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A chemical screen of approximately 2000 small molecules in zebrafish embryos identified a 
compound that generated pericardial edema, suggesting aberrant renal development. Treatment 
with this compound, 4-(phenylthio)butanoic acid (PTBA), increased the size of the pronephric 
kidney in zebrafish. Earlier in development, PTBA expanded the expression of renal progenitor 
cell markers, including lhx1a, pax2a, and pax8. Blocking DNA synthesis with hydroxyurea and 
aphidicolin before PTBA treatment decreased its efficacy, suggesting that PTBA-mediated renal 
progenitor expansion is proliferation dependent. Structure-activity analysis revealed that PTBA 
was an analog of the known histone deacetylase inhibitors (HDACis) 4-phenylbutanoic acid 
(PBA) and trichostatin A (TSA). Like PTBA, PBA and TSA both demonstrated the ability to 
expand lhx1a expression in treated embryos. PTBA was subsequently confirmed to function as 
an HDACi both in vitro and in vivo. HDACis are hypothesized to stimulate retinoic acid (RA) 
signaling by decreasing the concentration of RA necessary to activate RA receptors (RARs) on 
target genes. Indeed, treatment with PTBA affected the expression of the RA-responsive genes, 
cyp26a1 and cmlc2, in a manner consistent with increased RA signaling. Furthermore, blocking 
the RA pathway with a dominant-negative RARα construct decreased PTBA efficiency. 
Therefore, PTBA appears to stimulate renal progenitor cell proliferation by activating the RA-
signaling pathway. HDACis have been shown to improve renal recovery following acute kidney 
injury. Since PTBA increases renal progenitor cell proliferation, it may exert similar effects on 
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the multipotent cells involved in regeneration. In an effort to improve PTBA efficacy for 
pharmacological applications, analogs were generated by modifying the key structural elements 
of the general HDACi pharmacophore. These were tested along with a panel of known HDACis 
for their ability to increase lhx1a expression in treated embryos. Several compounds were 
characterized that function at nanomolar concentrations and do not cause toxicity in kidney cell 
culture. These second generation PTBA analogs are excellent candidates for development as 
potential renal therapeutics.     
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1.0  INTRODUCTION 
1.1 PHYSIOLOGICAL ROLES OF THE KIDNEY 
In his classic work From Fish to Philosopher, esteemed renal physiologist Homer W. Smith 
argues that our kidneys provide the means for our physiological freedom: 
Our bones, muscles, glands, even our brains, are called upon to do only one 
kind of physiological work, but our kidneys are called upon to perform an 
innumerable variety of operations. Bones can break, muscles can atrophy, 
glands can loaf, even the brain can go to sleep, and endanger our survival; 
but should the kidneys fail in their task neither bone, muscle, gland nor brain 
could carry on.1 (p. 4) 
This statement underscores the importance of our kidneys in permitting the complex 
biochemical processes that govern our daily lives. Indeed, renal failure not only compromises 
musculoskeletal, endocrine, and neurologic function, as mentioned by Dr. Smith, but also affects 
most other organ systems.2 The widespread pathology that arises reflects the critical 
physiological responsibilities of our kidneys. These include excreting metabolic wastes, 
maintaining water and electrolyte balance, performing gluconeogenesis, and secreting hormones 
regulating blood pressure, calcium uptake, and erythrocyte production.3 
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1.2 THE NEPHRON 
The nephron serves as the functional unit of the kidney.4 In adult vertebrates, each nephron 
consists of a renal tubule and an encapsulated capillary tuft, known as a glomerulus.5 Blood 
filtration begins at the fenestrated glomerular basement membrane, which excludes 
macromolecules from entering the capsular space based on their size and charge.6 The filtrate 
then enters the renal tubule which reabsorbs virtually all of the water and electrolytes, 
concentrating wastes for excretion in the urine.7 A healthy adult human kidney typically contains 
between 800,000 and 1,200,000 nephrons, with variation arising from age, sex, ethnicity, and 
birth weight.5,8 However, other vertebrates, including mice, amphibians, and fish, manage to 
maintain normal renal function with a fraction of the nephrons that humans require.5,9 
Furthermore, simple kidneys containing only a few nephrons sustain all vertebrates during the 
early phases of development. 
1.3 STAGES OF VERTEBRATE KIDNEY DEVELOPMENT 
The vertebrate kidney passes through up to three developmental stages of increasing complexity: 
the pronephros, mesonephros, and metanephros (Figure 1).10  
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Figure 1. Stages of vertebrate kidney development. 
1.3.1 The pronephros 
The composition of the first kidney, the pronephros, varies between active and rudimentary 
forms depending on the requirements of the developing organism. Vertebrates living in 
freshwater must constantly excrete the excess water entering their bodies and consequently must 
also reabsorb electrolytes to prevent ion depletion.11 Therefore, during the development of fish, 
amphibians, and certain reptiles, the pronephros must serve as a functional embryonic kidney.5 
Active pronephroi typically contain a pair of bilateral nephrons.5 Each consists of an anterior 
capillary tuft emptying into a tubule which connects to the urinary opening via a pronephric 
(nephric) duct.5 Importantly, the functioning pronephroi of fish and amphibians contain cell 
types typical of more complex kidneys, making them excellent model systems.12,13 
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Other vertebrates, including mammals and birds, enjoy protection from the osmotic 
demands of the external environment because they develop within an egg or uterus.14 Combined 
with the assistance of an allantois or placenta to remove wastes, these conditions preclude the 
need for renal function during early development.14 Therefore, their pronephroi primarily consist 
of vestigial structures, including short regions of tubule and duct, which almost certainly lack 
excretory capability.10,15 However, proper formation of the pronephros, whether active or 
inactive, is necessary to induce the development of more complex kidneys.10 Mauch and 
coworkers demonstrated this concept by observing that excision of chick pronephroi prevents the 
formation of the subsequent kidney form, the mesonephros.16 
1.3.2 The mesonephros 
The mesonephros functions as the adult kidney in fish and amphibians, and the embryonic 
kidney in other vertebrates.5 Mesonephric development begins with the formation of condensates 
known as renal vesicles from the mesenchymal tissue surrounding the nephric duct or tubule.10 
Renal vesicles then proceed through two morphological stages, the comma- and S-shaped body, 
before becoming mesonephric nephrons.4 In mammals and birds, extension of the nephric duct 
toward the urinary opening induces nephron formation in an anterior to posterior pattern.14,17 
Mesonephric nephrons in fish and amphibians arise in a similar manner, even though their 
nephric ducts already connect to the urinary opening.9,18  
In fish and amphibians, where the mesonephros represents the terminal adult kidney, 
hundreds or thousands of well-formed nephrons typically develop.5,9 Conversely, in other 
vertebrates, where the mesonephros serves only as a transitory organ, nephron numbers rarely 
exceed 60.5 Furthermore, many of the posterior nephrons exhibit primitive morphology and fail 
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to connect to the nephric duct.14 For example, of the approximately 18 nephrons of the mouse 
mesonephros, only 4 to 6 anterior nephrons actually fuse with the nephric duct.5 In almost all 
vertebrates, formation of the mesonephros triggers the degeneration of the now-obsolete 
pronephros.5 However, in some fish, the pronephros becomes repurposed as a lymphoid organ, 
known as the head kidney, and persists into adulthood.5 Similarly, the mesonephros will 
eventually adopt several new roles after ceding its renal responsibilities to its successor, the 
metanephros. 
1.3.3 The metanephros 
The terminal and most complex kidney, the metanephros, provides renal function to adult 
mammals, birds, and reptiles.19 Metanephric development begins with the establishment of a 
blastema of cells, known as the metanephric mesenchyme (MM), expressing the transcription 
factors Wt1 and Pax2.20,21 Subsequently, the MM secretes glial-cell-line derived neurotrophic 
factor to induce outgrowth of the ureteric bud (UB) from the posterior nephric duct.22 As the UB 
invades the MM, signals from the MM trigger repeated branching morphogenesis events, 
creating the collecting ducts of the metanephros.4 At the same time, the UB branches reciprocate 
by inducing condensation of the MM into renal vesicles.4 These will develop into metanephric 
nephrons by proceeding through the comma- and S-shaped body stages in a similar manner to 
mesonephric nephrogenesis. Reciprocal induction between the MM and UB continues until 
terminated by an unknown factor, thought to originate from differentiating MM.23 
As the metanephros becomes active, the mesonephros begins to degenerate and ceases its 
renal function.5 However, some portions of the mesonephros will become incorporated into the 
developing reproductive tract. In females, the nephric duct completely degenerates, but in males, 
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testosterone induces the duct to become the epididymis, vas deferens, and seminal vesicles.24 In 
both sexes, some mesonephric cells migrate to the adjacent primordium and contribute to the 
formation of the adrenal glands and gonads.4  
Fully-formed metanephroi contain anywhere from thousands of nephrons (mice) to about 
a million nephrons (human), depending on organism size and renal requirements.5 Importantly, 
the completion of the metanephros represents the end of new nephron development, also known 
as neonephrogenesis.5,25 Therefore, as the metanephros grows in a maturing organism, the 
existing nephrons respond by increasing in cell density and length, but not number. 26  
1.4 ORIGIN OF THE PRONEPHROS 
Although the pronephros forms the foundation for subsequent kidney development, this 
foundation depends on inductive events occurring long before the first nephron appears. The 
pronephros arises from the intermediate mesoderm (IM), located within the embryonic trunk 
between the paraxial and lateral-plate mesoderm.10 As embryos emerge from gastrulation, the 
presumptive IM undergoes specification to a kidney fate, creating a population of renal 
progenitor cells.27 The process of specification signifies that renal progenitor cells will 
differentiate into kidney in the absence of further inductive events.28 However, as the definition 
suggests, specified renal progenitor cells retain some developmental plasticity. As James and 
Schultheiss demonstrated in chick, transplanting specified IM to the lateral plate (LP) transforms 
many grafted cells to an LP fate.27  
Following specification, signals from nearby tissues define the boundaries of the 
emerging IM and trigger expression of the first IM-specific markers: Pax2, Lhx1, and Osr1.16,29-
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31 Later in development, during early somitogenesis, renal progenitor cells become irreversibly 
committed (or determined) to a kidney fate.27,28,32 At this point, IM transplanted to another 
embryonic environment continues to express IM-specific markers and fails to integrate into the 
host tissue.27,32 However, committed renal progenitor cells will continue to respond to a variety 
of molecular signals that will prepare the nascent kidney field for pronephric morphogenesis.      
1.5 MOLECULAR CONTROL OF PRONEPHRIC DEVELOPMENT 
Formation of the pronephros requires input from multiple signaling pathways acting in concert 
(Figure 2).15,33,34 A comprehensive review of all molecular mediators involved in this process 
sits beyond the scope of my work. Instead, I will discuss only the elements directly related to 
understanding of the experimental data. These include the Pax and Lhx proteins, transcription 
factors serving as early markers of renal progenitor cells, and the retinoic acid pathway.      
1.5.1 Pax pathway 
The paired-box (Pax) family of transcription factors directs the organogenesis of many tissues, 
including the central nervous system, pancreas, thyroid, and kidney.35 Each of the nine Pax genes 
encodes their namesake DNA-binding domain, along with a homeodomain and/or an 
uncharacterized octapeptide motif.36 The unique combinations of these domains further 
categorize the family into four well-defined groups.36 Of these, only two members of group II, 
Pax2 and Pax8, exhibit any expression in the developing kidney.20,37 The other group II member, 
Pax5, coexpresses with Pax2 and Pax8 in the central nervous system, but not elsewhere.38  
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Figure 2. Summary of developmental and molecular events forming the active pronephros. 
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Knockout studies revealed that mice carrying homozygous-null alleles of Pax2 fail to 
generate either mesonephric tubules or metanephroi.39 Although they still form nephric ducts, 
these extend only partway toward the urinary opening before beginning to degenerate.39 
Therefore, the lack of inductive signals resulting from a failure of duct extension explains the 
phenotype. Although not explicitly investigated by the authors, this also suggests that the loss of 
Pax2 interferes with pronephric development. In stark contrast, the kidneys of Pax8-deficient 
mice appear completely normal.40 The lack of phenotype probably reflects the ability of Pax2 to 
compensate for the loss of Pax8.41 Pax2 expression spans much of the developing mouse kidney 
and includes the more-restricted pattern of Pax8.40 Furthermore, evidence suggests functional 
redundancy between Pax2 and Pax5, providing additional support for a compensatory response 
among group II members.42 Importantly, mice homozygous-null for both Pax2 and Pax8 fail to 
form even the rudimentary nephric ducts observed in Pax2-deficient mice.29,39 The more severe 
phenotype exhibited by the double knockouts suggests that Pax8, like Pax2, also contributes to 
the development of the pronephros.  
Experiments utilizing zebrafish, Xenopus, and chick offer additional insights into the 
function of these genes.  In particular, the zebrafish pax2a mutant, no isthmus, provides a 
convenient platform for examining the regulatory relationships maintained by Pax2 during 
pronephric development.43 Homozygous expression of hypomorphic or null alleles of no isthmus 
prevents the formation of pronephric tubules and ducts, but spares the glomeruli.43-45 This occurs 
because pax2a specifies renal progenitor cells to the tubule and duct lineages, while wt1a drives 
cells to a glomerular fate.46 
Overexpression of Pax2 in chick embryos causes the formation of ectopic pronephric 
tubules and ducts.29 Similarly, pax8 overexpression in Xenopus embryos generates ectopic 
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tubules and, in addition, increases tubule size.41 These results again emphasize the important 
individual contributions of both Pax2 and Pax8 to proper pronephric development. However, the 
relationship between the two genes appears to vary among vertebrates. In mice, Pax2 and Pax8 
work together to initiate pronephric development by inducing renal progenitor cells to undergo a 
mesenchymal to epithelial transition.29 Moreover, this process occurs independently of any 
cross-regulation.29 In contrast, expression of pax8 during development of the zebrafish 
pronephros requires the presence of functional pax2a protein.47 The differing regulatory 
strategies of mice and zebrafish may reflect the evolutionary differences between rudimentary 
and active pronephroi.   
1.5.2 Lhx pathway 
The LIM homeobox protein (Lhx) family of nuclear transcription factors consists of over a dozen 
members that regulate the development of many tissue types.48 They are characterized by two 
unique zinc fingers, the LIM domains, located N-terminally to a DNA-binding homeodomain.49 
These LIM domains direct interactions with protein cofactors, resulting in the formation of active 
transcriptional complexes on target genes as specified by the homeodomain.48 The initial 
characterization of Lhx1 revealed that it was expressed in the developing kidneys of both 
Xenopus and mice.50-52 When Shawlot and Behringer later generated homozygous-null Lhx1 
mice, they observed that the rare stillborn neonates (4 out of about 1000) all lacked heads, 
gonads, and kidneys.53 A subsequent study using the same Lhx1-null line examined the effects of 
the mutation on formation of the pronephros.31 Loss of Lhx1 expression caused IM 
disorganization and restricted the expression of Pax2 in the emerging nephric duct to a short 
anterior region.31 However, the establishment of the IM remained unaffected, suggesting Lhx1 
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plays a role in IM differentiation, but not specification.31 Experiments in Xenopus kidney 
explants support this hypothesis. Treatment of Xenopus animal cap explants with both activin 
and retinoic acid (ARA) induces pronephric specification and subsequent tubulogenesis.54 Chan 
and coworkers demonstrated that overexpressing lhx1 in explants treated with either activin or 
retinoic acid was not sufficient to induce pronephric differentiation.55 However, expression of a 
dominant-negative form of lhx1 in ARA-treated explants prevented tubule formation.55 These 
results suggest that lhx1 is essential for pronephric tubulogenesis, but may not be primarily 
involved in kidney field specification.55 
Overexpression of lhx1 in Xenopus embryos causes the formation of both enlarged, as 
well as ectopic pronephric tubules.41 Moreover, lhx1 synergizes with either pax2 or pax8 to 
further increase pronephric size.41 Therefore, overexpression of these renal progenitor markers 
increases the pool of cells that will eventually be committed to the kidney fate. However, mice 
homozygous-null for Pax2 and Pax8 demonstrate no expression of Lhx1 in the developing 
nephric duct.29 This suggests that Lhx1 may act primarily as a competence factor that maintains 
the renal progenitor population following specification.29 
Dkk1, a Wnt signaling inhibitor, has emerged as a potential downstream effector of Lhx1. 
Conditional knockouts of Lhx1 in the kidneys of transgenic mice greatly reduced Dkk1 
expression.56 Furthermore, the phenotypes of Lhx1- and Dkk1-null mice appear very similar, 
although kidney phenotypes were not reported for the Dkk1 mutants.53,56,57 Significantly, the 
conserved non-coding elements in the Dkk1 locus contain conserved Lhx1-binding sites.58 
However, the observation that Dkk1 overexpression in transgenic zebrafish embryos inhibits 
differentiation of the pronephric tubule complicates this relationship.59 Perhaps, Lhx1 regulates 
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Dkk1 transcript levels in order to delimit the size of the pronephros as it undergoes 
differentiation. 
Little is known regarding the molecular factors that control the expression of Lhx1. 
Indeed, this represents part of the impetus for performing this dissertation work. However, 
several groups have hypothesized that Lhx1 regulation, as well as other aspects of pronephric 
development, require input from the retinoic acid pathway.  
1.5.3 Retinoic acid pathway 
Retinoic acid (RA) signaling influences many aspects of vertebrate development, including cell 
survival, proliferation, specification, differentiation, and organogenesis.60 RA functions as a 
morphogen, a locally-produced signaling molecule acting at a distance to pattern tissue fields in 
a concentration-dependent manner.61 The RA concentration gradient is refined by the local 
expression of Raldh enzymes, which synthesize RA, and Cyp enzymes, which catalyze its 
degradation.61 RA alters gene expression by binding retinoic acid receptor (RAR)/retinoic X 
receptor (RXR) heterodimers located on the retinoic acid response elements (RAREs) of target 
genes.61 Receptor activation by RA alleviates transcriptional inhibition mediated by a 
corepressor complex containing histone deacetylases (HDACs) and other factors.62 
Experimental manipulation of RA levels in embryos reveals that the pathway performs 
important functions during pronephric development. In Xenopus, stimulating signaling with 
exogenous RA increases the expression of pax8 and lhx1 in the pronephric field.63 Furthermore, 
RA-dependent kidney field expansions have also been reported for Lhx1 in chick and wt1a in 
zebrafish.64,65 In fact, a retinoic acid response element shown to bind RAR/RXR dimers in vitro 
was recently characterized in the zebrafish wt1a enhancer.66 Treating Xenopus embryos with RA 
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also positively regulates the expression of the Irx genes, which likely function as competence 
factors during pronephric development.67 Conversely, blocking the RA pathway decreases 
expression of pax2, pax8, and lhx1 in the Xenopus pronephric field and eliminates wt1a 
expression.63  
The ability of RA to affect the expression of renal progenitor markers suggests that the 
pathway may be involved in specification of the pronephric field. Indeed, treating Xenopus 
animal pole explants with both activin, a mesodermal inducer, and RA functions synergistically 
to induce lhx1 expression.52 Furthermore, treating mouse embryoid bodies, in vitro models of 
early embryogenesis,68 with RA stimulates the expression of Pax2 and Wt1 more than 20-fold.69 
These data, taken together, support the idea that RA serves as an important factor in renal 
progenitor cell specification. 
Two hypotheses have emerged to explain the effects of RA signaling on formation of the 
pronephric field. The first, supported by Cartry and coworkers, suggests that RA exerts a direct 
effect on renal progenitor cells.63 They observed that cycloheximde treatment, which inhibits 
protein synthesis, failed to prevent an RA-dependent increase in lhx1 expression during Xenopus 
pronephric development.63 Therefore, they concluded that RA did not require protein mediators 
to regulate lhx1.63 However, no RAREs have been reported in the Xenopus lhx1 promoter to date. 
Alternatively, RA could exert an indirect effect. This hypothesis, proposed by Preger-Been Noon 
and coworkers, is based on their observation that expression of the homeobox gene, Hoxb4, 
increased following RA treatment in chick embryos.64 RA directly regulates Hoxb4 expression,70 
and overexpression of Hoxb4 expands the expression of both Pax8 and Lhx1 in the chick 
pronephric field.64 Work by Taira and coworkers supports this hypothesis.71 They observed that 
RA treatment induces the expression of hoxb4 in the Xenopus pronephric field prior to the 
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appearance of lhx1.71 In addition, the expression domains of hoxb4 and lhx1 overlap, greatly 
improving the likelihood of interactions.71 Regardless of the true mechanism, both hypotheses 
emphasize the importance of RA in patterning the pronephric fields of several vertebrate models, 
including zebrafish. 
1.6 APPLICATIONS OF THE ZEBRAFISH MODEL 
The zebrafish (Danio rerio), a small freshwater vertebrate native to India, first emerged as an 
experimental model in the 1950's.72 The initial studies by Kenichi Hisaoka investigated the 
effects of small molecules, including carcinogens and barbiturates, on zebrafish development.73-
76 Despite these efforts, zebrafish publications rarely appeared over the next several decades, 
primarily due to a lack of genetic and molecular tools. In the 1980's, pioneering work by George 
Streisinger provided several useful techniques, laying the foundation for the current popularity of 
the zebrafish model.77,78 
Zebrafish gained acceptance over the years as researchers came to appreciate the 
advantages they offer over other vertebrate models. Depending on age, adult zebrafish typically 
measure between 2 to 5 cm, their small size limiting housing requirements and husbandry 
costs.79,80 Breeding pairs regularly produce hundreds of embryos per mating, providing the 
necessary numbers for even high-throughput applications.81 Conveniently, fertilization occurs ex 
utero, greatly simplifying embryo collection and manipulation.72 Embryos develop rapidly, 
initiating organogenesis by 24 hours post-fertilization (hpf) and forming most organs by 48 
hpf.81,82 The optical transparency of zebrafish embryos allows the observation of these processes 
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without the need for dissection or sacrifice.83 In addition, at only a few millimeters in length, 
embryos fit easily into microwell plates, facilitating screening and automation.72 
Zebrafish also exhibit qualities common to all widely-used vertebrate model systems. 
Their generation time of two to four months rivals that of mice and Xenopus tropicalis, making 
them comparably useful for genetic analyses.80,84,85 Furthermore, all vertebrate embryos develop 
under the control of a highly-conserved program of patterning events.79 Consequently, zebrafish 
exhibit the same general body plan as mammals, consisting of many homologous organs and cell 
types.86 Importantly, the molecular and genetic tools currently used in zebrafish mirror those 
available in the mouse model. These include methods for transgenesis, mRNA overexpression, 
morpholino knockdown, and nuclease-based gene targeting.72,80,87-89 
However, the zebrafish model also presents a unique set of challenges that should be 
considered when assessing its experimental utility. Unlike inbred mouse strains, it is likely that 
independent laboratory stocks of the most commonly-used zebrafish strains are not isogenic.90 
Indeed, even in so-called "inbred" zebrafish lines, polymorphisms have been reported in 7% to 
11% of the tested loci.91 This variation could greatly complicate zebrafish techniques relying on 
genetic mapping, such as positional cloning.90,91 Furthermore, an ancient genomic event resulted 
in the duplication of approximately 30% of zebrafish genes in comparison to their mammalian 
orthologs.92,93 For some applications, particularly knockdown or mutational analysis, the 
presence of extra gene loci may present a significant challenge. In addition, the availability of 
immortalized zebrafish cells for in vitro experimentation remains limited, as few stable lines 
have been established.94,95 Finally, since antibodies are rarely raised against zebrafish proteins, 
finding antibodies that exhibit reactivity in zebrafish extracts can be difficult.  
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However, despite these limitations, the use of zebrafish in research has exploded over the 
past two decades; performing a PubMed search using the keyword "zebrafish" returns 18 articles 
from 1989, 531 articles from 1999, and 1686 articles from 2009.96 The applications of the 
zebrafish model span a number of disciplines, each benefitting differently from its use. Studies of 
infection and immunity take advantage of the well-developed immune system of the zebrafish, 
which functions much like its mammalian counterpart.97,98 Toxicologists use the rapid embryonic 
development of zebrafish to assess chemicals for lethality or teratogenicity in a matter of days, 
rather than weeks.79 In addition, the small volumes needed to treat the embryos minimize the 
generation of hazardous waste, especially in high-throughput experiments.79 Researchers 
investigating human genetic disorders employ a number of relevant zebrafish models, generated 
from a long history of random and targeted mutagenesis studies.99-101 Zebrafish also demonstrate 
their value in the areas of kidney development and drug discovery, both of which constitute 
important parts of this dissertation.  
1.6.1 Modeling kidney development 
The early inductive events involved in patterning all three forms of the adult kidney likely have 
much in common.102 Indeed, both pronephric and metanephric kidneys require input from factors 
such as Pax2 and Lhx1 to initiate development.34,103 Therefore, the program of morphogenesis 
and epithelialization generating the two nephrons of the zebrafish pronephros probably reflects 
aspects of nephrogenesis in all vertebrates.102 In zebrafish, this process occurs in four general 
steps.12,104 Around 12 hpf, inductive signals affecting the IM specify some mesenchymal cells to 
a nephric fate, forming the first renal progenitor cells.12,104 By 24 hpf, additional signals trigger 
the renal progenitor cells to undergo a mesenchymal to epithelial transition, forming the nephric 
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tubules and ducts.12,104 Subsequent patterning of the glomerular capsule and anterior tubules, 
which takes place between 30 and 40 hpf, prepares the emerging nephron for operation.12,104 
Finally, invasion of the glomerular capsule by a capillary tuft completes the process of 
nephrogenesis and allows renal filtration to begin by 48 hpf.12,104  
 At this point, the zebrafish pronephros contains cells characteristic of metanephric 
nephrons. In the glomerulus, a fenestrated endothelium lines one side of the basement 
membrane, while extended podocyte foot processes protect the other.12 In the tubule and duct, 
polarized epithelia have formed which exhibit apical brush borders, well-defined cell junctions, 
and ion-transport proteins.104 Furthermore, recent studies have determined that zebrafish 
pronephric nephrons express segment-specific genes in a pattern consistent with that of 
mammalian metanephric nephrons.105 Thus, in only two days of development, zebrafish provide 
a relevant model of both mammalian nephrogenesis and renal function. 
In addition, several techniques available in the zebrafish model emphasize its value for 
studies of kidney development and function. Transgenic reporter lines for genes such as lhx1a 
and pax2a allow the real-time observation of renal progenitor cells in live embryos.106,107 Kidney 
function can be easily assessed by injecting a 10 kD fluorescent dextran into the zebrafish 
circulatory system and monitoring its passage into the tubular lumen.108 Alternatively, injecting a 
500 kD dextran, which should be retained in a healthy kidney, tests the integrity of the filtration 
barrier for glomerular leakage.109 Furthermore, researchers have developed many models of renal 
dysfunction in zebrafish. Damaging the pronephric tubules or glomerulus with nephrotoxic 
chemicals, for example, generates models of acute renal failure and minimal change disease, 
respectively.110-112 Genetic analysis has also contributed a wide selection of valuable mutants, 
including models of polycystic kidney disease, ciliopathies, and proteinuria. 77,82-84  
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1.6.2 Drug discovery 
Of all the vertebrates, zebrafish are probably the best suited for high-throughput drug discovery 
using forward chemical genetics.83 This approach involves screening small-molecule libraries to 
identify compounds capable of generating a desired phenotype.113 Forward screens in zebrafish 
offer several advantages over classical reverse chemical screens, which seek compounds binding 
a specific target of interest in vitro.113 Zebrafish cells appear in their normal context of cell-cell 
and cell-matrix interactions, unlike those maintained in culture.114 Furthermore, performing 
whole-organism screens allows the examination of complex processes, such as organogenesis, 
that are not easily reproduced in vitro.113 Screening in zebrafish also simultaneously provides 
animal testing data.114 Therefore, compounds generating phenotypes likely possess favorable 
properties for future pharmacological development.114 
Zebrafish embryos absorb small molecules directly from their culture environment, 
removing the need for labor-intensive microinjections.115 However, since compounds must 
penetrate cell membranes to enter the embryo, typically only hydrophobic compounds exhibit 
biological activity.116 Zebrafish embryos also develop normally in up to 1% dimethyl sulfoxide 
(DMSO), which frequently serves as a vehicle to improve compound solubility.114,117 Therefore, 
it is often possible to test several compound concentrations from a single DMSO stock.114 The 
ability to array zebrafish embryos in microwell plates permits screening in small volumes, 
minimizing compound costs.97 This also facilitates automation, which has been successfully 
applied to observe the effects of small molecule libraries on zebrafish behavior.118,119 Moreover, 
the emergence of sophisticated algorithms capable of detecting reporter fluorescence in 
transgenic lines offers a powerful tool for future high-throughput chemical screens.120-122  
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Zebrafish have been successfully used to identify interesting compounds in over a dozen 
published small molecule screens.72,114 Compounds have been characterized that modulate 
aspects of zebrafish development and physiology, including heart rate,120 hematopoiesis,123 
central nervous system morphogenesis,124,125 ear development,125 or even behavior.118,119 
Furthermore, zebrafish screens have revealed small molecules capable of influencing the bone 
morphogenetic protein (BMP),126 fibroblast growth factor (FGF),127 prostaglandin,128 and RA 
signaling pathways.116 Importantly, a study by Cao and coworkers demonstrated that screening 
small molecule libraries in zebrafish is a viable approach in examining aberrant kidney 
development.129 They observed that treatment with histone deacetylase inhibitors (HDACis) 
suppressed cyst formation and axis curvature in zebrafish models of polycystic kidney disease.129 
Therefore, using zebrafish to screen for small molecules interfering with kidney development 
may also promote the identification of compounds affecting renal progenitor cells. 
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2.0  IDENTIFICATION AND CHARACTERIZATION OF PTBA 
2.1 HYPOTHESIS 
In 2004, the Hukriede lab performed an unbiased chemical library screen on zebrafish embryos, 
seeking small molecules capable of generating edemic phenotypes. Since edema may reflect 
renal dysfunction130, they hoped to identify compounds capable of interfering with normal 
pronephric development. Determining the mechanisms of such compounds would provide 
insight into the molecular events guiding the specification of renal progenitor cells. Of the almost 
2000 compounds tested, only four caused embryos to develop edema by the 72 hpf endpoint. 
One of these, 4-(phenylthio)butanoic acid (PTBA), demonstrated the ability to increase the 
expression of renal progenitor cell markers. After joining the lab in 2006, I began working to 
further characterize the effects of PTBA on the kidney field. I hypothesized that PTBA increased 
the number of renal progenitor cells, resulting in aberrant pronephric development. 
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2.2 RESULTS 
2.2.1 PTBA causes edema in zebrafish larvae 
Rachel Jackson performed the initial chemical screen using a library of small molecules with 
diverse structures. She observed that 61 compounds (3%) were lethal and identified four 
compounds (NSC115787, NSC134664, NSC357777, and NSC35400) that generated pericardial 
edema in treated zebrafish larvae at 72 hpf (Figure 3). 
 
 
Figure 3. Four compounds causing pericardial edema in the initial phenotypic screen. (A 
through D) Top panels: chemical structures of NSC115787 (A), NSC134664 (B), 
NSC357777 (C),  or NSC35400 (D). Bottom panels: edemic phenotypes in 72 hpf larvae 
treated with the corresponding compounds at 10 µM. Data generated by Rachel Jackson. 
 
 In situ hybridization performed by Rachel and Guangzu Gao determined that treatment 
with NSC134664, NSC357777, or NSC35400 (a disconnected structure) did not affect the size of 
the kidney field (data not shown). However, Rachel observed that treatment with various 
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concentrations of 4-(phenylthio)butanoic acid (PTBA, NSC115787) appeared to expand the 
expression of some renal markers during pronephric development (data not shown). To ensure 
experimental reproducibility, Dr. Weixiang Dai of the Department of Pharmaceutical Sciences 
synthesized and purified PTBA for use in all subsequent studies. 
2.2.2 PTBA expands the kidney field 
To determine the concentration of PTBA that maximized efficacy, while minimizing toxicity, I 
performed concentration-response experiments. Treatment with 3 µM PTBA caused 92% (n = 
88) of the embryos to develop an edemic phenotype by 72 hpf without causing significant death 
(Figure 4). Therefore, I chose 3 µM PTBA as my working concentration. All embryos treated 
with 10 µM PTBA (n = 90), the concentration used in the initial screen, died before 72 hpf 
(Figure 4). This discrepancy probably reflects the concentration variability common in small 
molecule libraries.131  
The edemic phenotypes elicited by PTBA treatment, coupled with Rachel's preliminary 
observations, prompted me to examine whether the compound affects renal progenitor cells. To 
address this, I determined the expression patterns and relative abundance of lhx1a, pax2a, and 
pax8 at the 10-somite stage (14 hpf). This developmental stage occurs just after specification of 
the first renal progenitor cells.104 Lhx1a expression was expanded in 95% of embryos treated 
with PTBA (n = 60) as compared with controls (n = 60) (Figure 5, A and B). This represented a 
three-fold increase in relative transcript as determined by quantitative real-time PCR (qPCR; 
Figure 5, A and B). Increased lhx1a expression appeared in the bilateral stripes of intermediate 
mesoderm that give rise to the pronephros (Figure 5B, arrowheads), as well as in the axial 
mesoderm (notochord; Figure 5B, asterisk).  
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Figure 4. PTBA elicits concentration-dependent effects on larval edema and survival. (A 
through D) Embryos were treated with 0 to 10 µM PTBA from 2 hpf, and larvae were scored 
at 72 hpf using a phenotype-based classification system (see Methods). (A) Wild-type (WT). 
(B) Edemic 1 (E1). (C) Edemic 2 (E2). (D) Edemic 3 (E3). (E) Graph of phenotypes after 
treatment with 0 to 10 µM PTBA (n = 90 per concentration). Asterisk denotes lowest PTBA 
concentration that exhibits a significant effect (p < 0.05) on survival. 
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Figure 5. PTBA treatment increases the expression of renal progenitor markers. (A through 
F) In situ hybridization for lhx1a (A and B), pax2a (C and D), or pax8 (E and F), in 10-
somite embryos treated with 0.5% DMSO (A, C, and E) or 3 µM PTBA (B, D, and F). 
Arrowheads indicate renal progenitor cells, asterisk indicates notochord. Relative qPCR in 
the trunk region of 10-somite embryos (n = 4, 60 embryos per group) is displayed under the 
corresponding in situ image. Data are mean expression with 95% confidence interval, 
determined as described in the Methods section. 
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The expression domains of pax2a and pax8 were also expanded in 95% and 97% of 
treated embryos, respectively, (n = 60, pax2a; n = 59, pax8) as compared with controls (n = 60, 
pax2a; n = 59, pax8) (Figure 5, C through F). This accounted for an almost two-fold increase in 
pax2a expression and a 50% increase in pax8 expression as determined by qPCR (Figure 5, C 
through F).  
Although these studies demonstrated that PTBA treatment resulted in increased gene 
expression, they did not indicate whether there are more renal progenitor cells or simply higher 
expression levels per cell. To differentiate between these two possibilities, I treated the 
Tg(lhx1a:EGFP)pt303 reporter line107 with PTBA and counted the number of renal progenitor 
cells. As compared with control embryos, PTBA-treated embryos showed a 2.4-fold increase in 
the number of renal progenitor cells (Figure 6, A through H).  
2.2.3 PTBA is effective during specification 
Previously, Rachel had performed a temporal assay to determine the timing of PTBA 
efficacy. Initiation of PTBA treatments between 2 hpf and 14 hpf (10 somites) resulted in 
expanded pax2a expression at 24 hpf (Figure 7, A through F). However, beginning treatment at 
16.5 hpf (15 somites) resulted in no kidney field expansion (Figure 7G). I later determined that 
initiating treatments at 15 somites or later did not affect the functional kidney as assayed by a 
lack of edema in 72 hpf larvae (n = 90, data not shown). Thus, the effective temporal treatment 
window exhibited by PTBA coincides with the period when renal progenitor cells are 
specified.46,104 
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Figure 6. PTBA treatment increases the number of renal progenitor cells. (A through H) 
Confocal projections of 10-somite Tg(lhx1a:EGFP)pt303 embryos treated with 0.5% DMSO 
(n = 18 [A through D]) or 3 µM PTBA (n = 21 [E through H]). Boxed areas (A and E) were 
counted for GFP- and DAPI-positive nuclei and are shown in B and F (GFP), C and G 
(DAPI), and D and H (merge). Cell counts are mean number of positive cells plus 95% 
confidence interval (A and E). Confocal microscopy performed by Lisa Antoszewski.  
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Figure 7. PTBA is effective during renal progenitor cell specification. (A through G) In situ 
hybridization for pax2a in 24 hpf embryos treated with 0.5% DMSO from 2 hpf (A, n = 132)  
or 3 µM PTBA from: 2 hpf (B, n = 67), shield (C, 6 hpf, n = 100), 2 somites (D, 10.7 hpf, n = 
71), 5 somites (E, 11.7 hpf, n = 87), 10 somites (F, 14 hpf, n = 89), or 15 somites (G, 16.5 
hpf, n = 72). Insets are pax2a enlargements (lower field). Data generated by Rachel Jackson. 
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2.2.4 PTBA increases pronephric size 
To determine whether PTBA treatment resulted in a transient or persistent expansion of the 
kidney field, I examined the kidney at 48 hpf using markers of glomerulus and tubule. 65,108,132 
As compared with controls (n = 54), 89% of PTBA-treated embryos (n = 56) displayed an 
expansion of the pan-tubule marker cdh17 (Figure 8, A through D). Cross-sections from the 
proximal region of the cdh17 expression domain confirmed the expansion (Figure 8, E and F). 
I also assessed pronephric expansion at the protein level by examining the expression of 
NaK-ATPase, another pan-tubule marker (Figure 9, A and B). As compared with controls (n = 
10), 100% of PTBA-treated embryos (n = 10) exhibit expansion of NaK-ATPase protein 
expression. Cross-sections taken from the distal region of the NaK-ATPase expression domain 
show an increase in tubular diameter consistent with that observed with cdh17. (Figure 9, C and 
D, compare with Figure 8, E and F). 
To determine if PTBA exhibits any segment-specific effects on the size of the 
pronephros, I examined markers of podocytes (wt1a), proximal tubule (slc4a4), and distal tubule 
(slc12a1). As compared with controls (n = 57, 58, and 56, respectively), PTBA-treated embryos 
exhibited 74% expansion of wt1a (n = 50), 92% expansion of slc4a4 (n = 60), and 64% 
expansion of slc12a1 (n = 59) (Figure 10). These results argue that PTBA treatment likely 
causes expansion of the entire pronephros. Furthermore, while the wt1a expression domains in 
control embryos have migrated to the midline by 48 hpf, the domains of PTBA-treated embryos 
remain separated (Figure 10, A and B). Since wt1a is essential for proper glomerular 
morphogenesis,133 this misexpression may contribute to a loss of kidney function. This 
observation could explain the edemic phenotypes associated with PTBA treatment.  
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Figure 8. PTBA treatment expands cdh17 expression. (A through D) In situ hybridization for 
cdh17 expression in 48 hpf embryos treated with 0.5% DMSO (A [magnified in B]) or 3 µM 
PTBA (C [magnified in D]). (E and F) Proximal tubule cross-sections (5 µm) taken from 
cdh17 in situ hybridizations of 48 hpf embryos treated with 0.5% DMSO (E) or 3 µM PTBA 
(F). Cross-sections were taken from the locations indicated in B and D by yellow lines. 
Sectioning performed by Chiara Cianciolo Cosentino. 
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Figure 9. PTBA treatment expands NaK-ATPase expression. (A and B) Whole-mount 
antibody staining for NaK-ATPase in 48 hpf embryos treated with 0.5% DMSO (A) or 3 µM 
PTBA (B). (C and D) Distal tubule cross-sections (5 µm) taken from NaK-ATPase antibody-
stained 48 hpf embryos treated with 0.5% DMSO (C) or 3 µM PTBA (D). White arrowheads 
indicate NaK-ATPase protein expression. Cross-sections were taken from the locations 
indicated in A and B by yellow lines. Sectioning performed by Chiara Cianciolo Cosentino. 
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Figure 10. PTBA treatment expands several pronephric regions. (A through F) In situ 
hybridization for the podocyte marker wt1a (A and B), the proximal tubule marker slc4a4 (C 
and D) and the distal tubule marker slc12a1 (E and F) in 48 hpf embryos treated with 0.5% 
DMSO (A, C, and E) or 3 µM PTBA (B, D, and F). Brackets in A and B indicate the 
expression domain of wt1a.  
2.2.5 PTBA does not transform neighboring tissues to a kidney fate 
The PTBA-mediated increase in kidney field size could result from the transformation of non-
renal cells to a renal progenitor fate. To assess this possibility, I examined the effects of PTBA 
on markers of two mesodermal tissues juxtaposed to renal progenitor cells: myod1 (somites) and 
fli1a (vasculature). By in situ hybridization, I observed that myod1 expression was slightly 
decreased in 95% of PTBA-treated embryos (n = 60) at the 10-somite stage, as compared with 
controls (n = 60) (Figure 11, A and B). However, subsequent qPCR analysis did not confirm the 
significance of this observed decrease (Figure 11, A and B). Expression of fli1a remained 
unchanged in 97% of PTBA-treated embryos (n = 60), as compared with controls (n = 59), and 
as assayed by qPCR (Figure 11, C and D).  
 In addition to increased lhx1a expression in renal progenitor cells, I had also observed 
increased lhx1a expression in the notochord (Figure 5B, asterisk). To determine whether this 
expansion reflected an effect on notochord size or a general increase in lhx1a expression, I 
assayed the notochord-specific marker ntla. I observed that ntla was increased in 88% of PTBA- 
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Figure 11. PTBA treatment does not transform nearby tissues to a renal fate. (A through F) 
In situ hybridization for the mesodermal markers myod1 (A and B), fli1a (C and D), and ntla 
(E and F) in 10-somite embryos treated with 0.5% DMSO (A, C, and E) or 3 µM PTBA (B, 
D, and F). Relative mRNA abundance in the trunk region of 10-somite embryos (n = 4, 60 
embryos per group) is displayed under the corresponding in situ image. Data are mean 
expression with 95% confidence interval, determined as described in the Methods section.  
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treated embryos (n = 60), as compared with controls (n = 59) (Figure 11, E and F). This 
represented an 80% increase in ntla expression by qPCR analysis (Figure 11, E and F). The 
minimal effect on juxtaposed tissues coupled with an increase in the size of the notochord 
suggests that these cell types are not being converted to renal progenitor cells. Therefore, PTBA 
treatment cannot be definitively linked to a fate-transformation event. 
2.2.6 PTBA requires proliferation for efficacy 
To examine the alternative possibility that PTBA-mediated renal progenitor cell expansion 
depends on cell proliferation, I tested the efficacy of PTBA in the presence of hydroxyurea and 
aphidicolin (HUA). HUA treatment has been previously shown to block cell division without 
affecting tissue specification.134 As expected, 97% of PTBA-treated embryos (n = 123) exhibited 
an expansion of lhx1a expression at 10 somites, as compared with controls (n = 136), (Figure 
12, A and B). HUA treatment alone did not affect lhx1a expression (Figure 12C). However, 
treatment with both HUA and PTBA resulted in lhx1a expansion in only 13% of 10-somite 
embryos (n = 104) (Figure 12D). Furthermore, although lhx1a expression was decreased in the 
intermediate mesoderm, expression in the axial mesoderm still appeared to be increased in 
treated embryos (Figure 12D). This result suggests that the PTBA-mediated lhx1a expansion in 
the axial region is proliferation independent. Since lhx1a expression in the axial mesoderm is 
gradually restricted to the tailbud during somitogenesis,107 the effect may reflect transcript 
perdurance. 
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Figure 12. PTBA requires proliferation for efficacy. (A through D) In situ hybridization for 
lhx1a expression in 10-somite embryos treated at 5 hpf with 0.5% DMSO (A and B) or HUA 
(C and D). At 8 hpf, treatment solutions were replaced with 0.5% DMSO (A), 3 µM PTBA 
(B), HUA (C), or 3 µM PTBA and HUA (D).  
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2.3 METHODS 
2.3.1 Zebrafish husbandry 
Zebrafish were maintained under standard conditions135 and staged as previously described.136 
Embryos were collected from group matings of wild-type AB adults. All animal husbandry 
adhered to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. 
2.3.2 Small molecule screening 
The screen was performed in zebrafish embryos using the National Cancer Institute's 
Developmental Therapeutics Program (NCI/DTP) Diversity Set I.137 This library contains 1990 
compounds selected by pharmacophore modeling to represent the more than 140,000 small 
molecules maintained in the NCI/DTP Open Repository. Compounds from the NCI/DTP 
Diversity Set I were diluted to 10 µM in E3 embryo medium (5 mM NaCl, 0.33 mM CaCl2, 0.33 
mM MgSO4, and 0.17 mM KCl) in a final DMSO concentration of 0.5% and arrayed in 96-well 
plates. Beginning at approximately 2 hpf, embryos were transferred to each well in groups of 
five using a glass pipette. The plates were incubated at 28.5 oC for 70 hours. Individual wells 
were then scored for a dominant phenotype, representative of at least four of the five embryos. 
The primary objective was to identify compounds that caused edema in treated embryos at 72 
hpf. Small molecules generating edema were retested once for verification, before obtaining 
additional compound from the NCI/DTP Open Repository. 
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2.3.3 Compound sources and treatments 
PTBA was synthesized as described below. Hydroxyurea and aphidicolin were obtained from 
Sigma-Aldrich. Groups of 20 to 30 chorionated 2 hpf embryos were arrayed in individual wells 
of 12-well plates. E3 medium was removed with a glass pipette and replaced with 1.5 ml 
treatment solutions containing 0.5% DMSO in E3 with or without compound at the reported 
concentrations. Treatments for all studies were initiated at 2 hpf, except for the temporal studies 
(Figure 7) and the HUA studies (Figure 12). HUA studies were performed as described 
previously,138 with the following modifications. HUA in 0.5% DMSO was added at early 
gastrulation (5 hpf) and PTBA was subsequently added at late gastrulation (8 hpf) to allow for 
penetration of the proliferation inhibitors. All embryos were incubated at 28.5 oC until the 
required developmental stage.   
2.3.4 Synthesis of PTBA 
 
Figure 13. Synthesis scheme for PTBA 
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Methyl 4-(phenylthio)butanoate (1) was prepared from thiophenol, potassium carbonate, and 
methyl 4-bromobutyrate in refluxing acetone as previously described.139 4-(phenylthio)butanoic 
acid (2) was prepared either in quantitative yield by saponification of 1 with aqueous KOH in 
MeOH overnight at room temperature followed by acidification with aqueous HCl, or in 97% 
yield from reaction of the sodium salt of thiophenol and γ-butyrolactone in refluxing EtOH and 
subsequent acidification with aqueous HCl as previously described.140 All compounds gave 1H 
and 13C NMR (400/100 MHz and/or 600/150 MHz), mass spectra (GC-EI-MS, LC-ESI-MS, and 
high-resolution MALDI-TOF-MS), and melting points consistent with the literature and their 
structures. All spectral and melting point data suggested >99% purity.139-141  
2.3.5 Concentration-response studies 
Following 70 hours of treatment (as described above), edemic phenotypes in 72 hpf larvae were 
scored using a phenotype-based classification system. Wild type: no visible edema or 
developmental delay. Edemic 1: pericardial edema evident, may exhibit slight developmental 
delay, little or no axis curvature, axis length normal. Edemic 2: pericardial edema evident, slight 
to moderate developmental delay, axis curvature, axis length normal or slightly reduced. Edemic 
3: pericardial edema evident, moderate to severe developmental delay, gross axis curvature 
frequently accompanied by tail kink, axis noticeably shortened. Significant effects (p < 0.05) on 
survival were determined by two-tailed Fisher's exact test in comparison with the 0 µM PTBA 
treatment group. 
 38 
2.3.6 In situ hybridization and immunocytochemistry 
In situ hybridization was performed as previously described with some modifications.142 
Hybridization temperature was 65 oC. Embryos were blocked in 2% blocking reagent (Roche) 
with 5% sheep serum in MAB (100 mM maleic acid and 150 mM NaCl [pH 7.5]). Whole-mount 
immunocytochemistry with 1:25 mouse anti-α6F antibody (Developmental Studies Hybridoma 
Bank) and 1:100 Cy3 secondary antibody (Jackson ImmunoResearch) was performed as 
described previously.108 Embryos were embedded in JB-4 for sectioning per the manufacturer's 
instructions (Polysciences), sectioned at 5 µm, and mounted with Cytoseal 60 (Richard-Allan 
Scientific).  
2.3.7 Relative qPCR 
2.3.7.1 cDNA synthesis 
Several of the genes analyzed by qPCR, including lhx1a and pax2a, show expression in anterior 
regions of the embryo as well as the IM. To focus more specifically on effects in the IM, I 
examined cDNA samples taken from the trunks of treated and control embryos. Samples for 
trunk RNA extraction were prepared by cutting embryos just above the first somite with 
microscissors and discarding the anterior portion. The trunk portions were homogenized with a 
plastic microcentrifuge pestle in 500 µL of TRI reagent (Ambion), and RNA was isolated using 
an RNeasy Micro Kit (QIAGEN) per the manufacturer's instructions. 1 µg RNA was heated to 
75 oC for 5 min and then placed on ice. The following reagents were then added to a final 
volume of 29 µl: 1X Expand High-Fidelity PCR buffer without MgCl2 (Roche), 3 mM MgCl2, 
500 µM dNTPs, 3.3 µM random hexamers, and 30 U Protector RNase Inhibitor (Roche). The 
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mixture was preincubated to 42 oC for 5 min. 1 µl of 200 U/µl SuperScript II Reverse 
Transcriptase (RT) or RNase-free water was added for +RT or –RT reactions, respectively. 
Reactions were incubated at 42 oC for 1 hr and then stopped by heating to 95 oC for 5 min. 
Reaction products were stored at -20 oC. 
2.3.7.2 Primer sets 
Primer sets were designed using NetPrimer and Beacon Designer (ver. 7.51) primer analysis 
software (PREMIER Biosoft). In each set, one primer was designed to span an exon boundary. In 
addition, at least one primer was confirmed to exhibit no significant cross-homology when 
compared against the NCBI zebrafish RefSeq mRNA library by BLAST search. Primer melting 
temperatures were maintained between 60 and 64 oC as determined by NetPrimer. Each primer 
set was observed to generate a single amplicon of expected length following qPCR. 
 The reference gene primer sets have been previously described143 with one modification. 
The β-actin (F) sequence was changed to: CGTGCTGTCTTCCCATCCA. This corrects a one-
base discrepancy from the reported ENSDART accession number. The other primer sets 
included: lhx1a (F): TTCATACTATGGAGATTATCAAAGCG, lhx1a (R): 
GGTCCTGATGAGGGAACAAAAG, pax2a (F): GTCCCTGGAAGCGACTTTTC, pax2a (R): 
TTGACTGGGCTGCGATGG, pax8 (F): GCTCCGCCGTCACTCCTC, pax8 (R): 
TCTCCTGGTCACTGTCATCGTG, ntla (F): CGCAGCACTACCACCAATAACTAC, ntla 
(R): GAGCCTGATGGGGTGAGAGTC, myod1 (F): TTCTGGAACATTACAGTGGAGACTC, 
myod1 (R): GTGCGTCAGCATTTGGTGTG, fli1a (F): CGGAAAAGGCTCTCCAACAG, fli1a 
(R): TGCTGGTGGGTCCTAATATCTG. 
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2.3.7.3 qPCR conditions 
Relative qPCR was performed as described previously143 with some modifications. 25 µl 
reactions were prepared containing the following reagents: 12.5 µl 2X iQ SYBR Green 
Supermix (Bio-Rad), 5 µl 1 µM primer mix (1 µM each of forward and reverse primer), 5.5 µl 
RNase-free water, and 2 µl 1:10-diluted template (+RT or –RT product) or 2 µl RNase-free 
water (no template control). Each assay was performed in triplicate wells using an iQ5 Real-
Time PCR Detection System (Bio-Rad). Thermal cycling was performed for 40 cycles, each 
consisting of 94 oC for 15 s, then 59 oC for 1 min. Following amplification, melt curve analysis 
was performed to assess non-specific amplification. Each primer set yielded a single peak, 
indicative of specific amplification. Reactions performed using –RT product or no template 
controls were observed to exhibit little or no amplification in comparison with their +RT 
counterparts.   
2.3.7.4 Reference gene determination 
Seven reference gene candidates [β-actin, β2 microglobulin, elongation factor 1 alpha, 
hypoxanthine guanine phosphoribosyl transferase 1, RNA polymerase subunit D, ribosomal 
protein L13a, and succinate dehydrogenase complex subunit A (SDHA)]143 were screened to 
determine the gene(s) least affected by PTBA treatment. Relative qPCR experiments (n = 3, 180 
embryos) were performed using trunk cDNA obtained from 10-somite embryos treated from 2 
hpf with either 0.5% DMSO or 3 µM PTBA. The results were analyzed using NormFinder 
software (ver. 0.953) to determine the most stable reference gene or combination of genes.144 
The combination of β-actin and SDHA was observed to exhibit the most stability, and was 
therefore used for normalization of all qPCR data. 
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2.3.7.5 Data analysis 
Relative gene expression was calculated using iQ5 software (ver. 2.0, Bio-Rad) to determine 
normalized expression levels (∆∆Ct method). For comparison of fold-differences, the expression 
levels obtained from DMSO-treated controls were set to a value of 1.0. The amplification 
efficiency of each reaction was calculated using LinRegPCR software (ver. 11.4).145 The mean 
efficiencies of each tested primer set fell between 91% and 100%.  Mean expression levels 
(normalized to the control group) and the corrected expression SD were used to generate 95% 
confidence intervals for each data set. 
2.3.8 Cell counting 
Tg(lhx1a:EGFP)pt303 embryos107 were treated with 3 µM PTBA and then fixed in 4% 
paraformaldehyde in PBS for 8 hours at 4 oC. Embryos were washed in PBS containing 0.1% 
TWEEN 20 (PBT) and incubated in 1 µg/ml DAPI in PBT for 30 minutes at room temperature. 
Embryos were flat-mounted on glass slides with Cytoseal 60 and imaged with either a Leica 
M205 FA epifluorescent microscope or an Olympus FluoView 1000 confocal microscope. 
Confocal projections contained stacks of six 3 µm images. 
 A predefined box was positioned at the most posterior region of the notochord and 
included the most lateral GFP-positive cell in a kidney field. The cells that were positive for both 
GFP and DAPI within this box were counted manually with the aid of ImageJ. Variances of the 
control and PTBA-treated groups were compared by F test and found to be unequal. Therefore, a 
two-tailed t test with unequal variance was used to determine significance (α = 0.05).   
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3.0  MECHANISM OF PTBA EFFICACY 
3.1 HYPOTHESIS 
Having established that PTBA stimulates renal progenitor cell proliferation (Chapter 2), I next 
attempted to determine the mechanism responsible for this effect. Initial structure-activity 
relationship experiments demonstrated that certain structural motifs within PTBA modify its 
efficacy. While these results provided important leads for future analog development, they did 
not reveal any clues to the underlying mechanism. The breakthrough came when subsequent 
analysis revealed that PTBA is structurally similar to known histone deacetylase inhibitors 
(HDACis), including 4-phenylbutanoic acid (PBA) and trichostatin A (TSA). HDACis are 
thought to attenuate retinoic acid receptor-mediated inhibition of target genes, lowering the 
threshold of retinoic acid (RA) required to activate transcription.62 Since RA affects pronephric 
development,63,65 I hypothesized that PTBA functions as an HDACi and its effects are mediated 
through the RA pathway.   
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3.2 RESULTS 
3.2.1 PTBA structure-activity studies reveal critical motifs 
I performed structure-activity analyses using a series of seven analogs (Figure 14). In situ 
hybridization for lhx1a was performed on 10-somite embryos treated with each analog at 3 µM. 
The results were compared with control (no expansion, n = 53) (Figure 14A) and PTBA-treated 
embryos (100% expansion, n = 52) (Figure 14B). I observed that replacement of the phenylthio 
ether with a phenylsulfonyl linkage stripped the compound of its effects on renal progenitor cells 
(no expansion, n = 54) (Figure 14C). Therefore, the oxidation state of the sulfur atom is a 
critical activity determinant. However, 4-(naphthalen-2-yl thio)butanoic acid, an analog carrying 
a naphthalene ring in place of the phenyl moiety of PTBA, still expands lhx1a expression to 
some extent (33% expansion, n = 39) (Figure 14D). Thus, modifications of the ring structure are 
tolerated and suggest a site for future analog development.  
 Two analogs containing substitutions of the butanoic acid backbone, 2-amino-PTBA and 
3-(phenylthio)benzoic acid had no effect on lhx1a expression (no expansion, n = 64 and n = 53, 
respectively) (Figure 14, E and F), suggesting a requirement for a flexible hydrocarbon 
backbone for biological activity. I also examined 4-phenoxybutanoic acid and 5-phenylpentanoic 
acid, which contain oxygen and carbon substitutions for the sulfur atom, respectively. 4-
Phenoxybutanoic acid exhibited reduced activity compared with the parent compound (13% 
expansion, n = 56) (Figure 14G), while 5-phenylpentanoic acid was inactive (no expansion, n = 
55) (Figure 14H). These results suggest that compound efficacy is improved when an atom with 
a nonbonding electron pair(s) occupies this position. Finally, the esterified analog methyl-4-
(phenylthio)butanoate exhibited equal potency to PTBA (100% expansion, n = 41) (Figure 14I). 
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Figure 14. Structure-activity relationship studies reveal essential moieties for PTBA 
efficacy. (A through I) In situ hybridization for lhx1a expression in 10-somite embryos 
treated with 0.5% DMSO (A) or 3 µM of the following compounds: PTBA (B), 4-
(phenylsulfonyl)butanoic acid (PSOBA) (C), 4-(naphthalen-2-ylthio)butanoic acid (D), 2-
amino-PTBA (E), 3-(phenylthio)benzoic acid (F), 4-phenoxybutanoic acid (G), 5-
phenylpentanoic acid (H), and methyl-4-(phenylthio)butanoate (I). 
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3.2.2 HDACis mimic the effects of PTBA 
Subsequent structural analysis revealed that PTBA is a close analog of 4-phenylbutanoic acid 
(PBA), a known HDACi (Figure 15, A and B), and that both compounds exhibit some similarity 
to the HDACi trichostatin A (TSA) (Figure 15C). Indeed, all three structures contain the 
elements of the HDACi pharmacophore, a general representation of the functional domains 
within this class of compounds (Figure 15D). These include an aliphatic or aromatic cap, 
connecting unit, hydrophobic linker, and zinc-binding group. 
 
 
Figure 15. PTBA exhibits structural similarity to HDACis. (A through D) Structures of 
PTBA (A), PBA (B), TSA (C), and the general HDACi pharmacophore (D) containing a cap 
(CAP), connecting unit (U), hydrophobic linker (LINKER), and zinc-binding group (ZBG).  
 
 Because PBA and TSA are structurally analogous to PTBA, I determined if they shared 
the same ability to expand renal progenitor cells. Concentration-response experiments were 
performed to determine the concentrations of PBA or TSA necessary to elicit lhx1a expansion, if 
any (Figures 16 and 17). 
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Figure 16. Treatment with the HDACi PBA expands the kidney field. (A through F) In situ 
hybridization for lhx1a in 10-somite embryos treated from 2 hpf with: 0.5% DMSO (A, n = 
59), 10 µM PBA (B, n = 58), 15 µM PBA (C, n = 60), 20 µM PBA (D, n = 59), 25 µM PBA 
(E, n = 58), or 30 µM PBA (F, n = 53). 
 
 
Figure 17. Treatment with the HDACi TSA expands the kidney field. (A through F) In situ 
hybridization for lhx1a in 10-somite embryos treated from 2 hpf with: 0.5% DMSO (A, n = 
60), 100 nM TSA (B, n = 57), 150 nM TSA (C, n = 57), 200 nM TSA (D, n = 52), 250 nM 
TSA (E, n = 42), or 300 nM TSA (F, n = 40). 
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 I determined that treatment with 25 µM PBA or 200 nM TSA produced an expansion of 
lhx1a expression consistent with that elicited by 3 µM PTBA (Figures 16E and 17D compared 
with Figure 5B). Therefore, at least two known HDACis mimic the effects of PTBA, supporting 
the idea that PTBA likewise functions as an HDACi. 
3.2.3 PBA and TSA exhibit greater toxicity than PTBA 
I next tested how trunk mesoderm juxtaposed to the kidney field is affected by PBA and TSA 
treatments. I previously determined that PTBA treatment does not significantly affect the 
expression of somitic or vascular markers (Figure 11, A through D) Furthermore, although 
PTBA increased ntla expression, the general structure of the notochord remained relatively 
unchanged (Figure 11, E and F). However, TSA is a broad-spectrum HDACi that causes 
disruption of multiple tissues in zebrafish and demonstrates renal toxicity in cell culture.146-148 
Therefore, I treated embryos with 25 µM PBA or 200 nM TSA and compared the expression of 
myod1, fli1a, and ntla with that of control embryos. Expression of myod1 was decreased in 57% 
of PBA-treated embryos (n = 53) and 100% of TSA-treated embryos, as compared to controls (n 
= 54) (Figure 18, A through C). Furthermore, TSA treatment caused an almost complete loss of 
the somitic blocks (Figure 18C). As compared with controls (n = 54), fli1a expression decreased 
in 78% of PBA-treated embryos (n = 54) and 95% of TSA-treated embryos (n = 55) (Figure 18, 
D through F). PBA increased ntla expression in 87% of treated embryos (n = 52), as compared 
to controls (n = 55) (Figure 18, G and H). This effect appears similar to the expanded ntla 
expression I observed following PTBA treatment (Figure 11F). In contrast, TSA disrupted 
normal ntla expression in 86% of treated embryos (n = 56), as compared with controls (Figure 
18, G and I). This resulted in breaks in the ntla expression pattern (Figure 18I, arrowheads). 
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Figure 18. Treatment with PBA or TSA affects nearby tissues. (A through I) In situ 
hybridization for myod1 (A through C), fli1a (D through F), or ntla (G through I) in 10-
somite embryos treated with 0.5% DMSO (A, D, and G), 25 µM PBA (B, E, and H), or 200 
nM TSA (C, F, and I). Arrowheads indicate breaks in ntla expression. 
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To determine the toxicity of PBA and TSA relative to PTBA, I again performed 
phenotypic concentration-response experiments. I assessed 72 hpf larvae for the development of 
edemic phenotypes over the same concentration range used to test for expansion of the kidney 
field. Pericardial edema was evident in 23% of larvae treated with 25 µM PBA (n = 83) and 
100% of larvae treated with 200 nM TSA (n = 35) (Figures 19 and 20).  In addition, 25 µM 
PBA caused minimal, but significant death (8%, n = 90), while treatment with 200 nM TSA 
resulted in high lethality (61%, n = 90) (Figures 19 and 20). 
3.2.4 PTBA functions as an HDACi in vitro 
Because PBA and TSA mimic the ability of PTBA to expand renal progenitor cells, I determined 
whether PTBA functions as an HDACi. To evaluate this in vitro, I measured the deacetylation of 
a fluorescent peptide substrate in the presence of human HDACs. HDAC activity increased in 
direct proportion to the amount of HeLa cell nuclear extract added to the assay (Figure 21, black 
triangle). Addition of TSA completely blocked activity at all input levels of nuclear extract 
(Figure 21, gray triangle). Previous work showed that 5 mM PBA decreased HDAC activity in 
DSI9 mouse erythroleukemia cells to 19% of the control value.149 To determine whether PTBA 
inhibited HDACs to a similar extent as PBA, I evaluated both compounds at 5 mM. PTBA and 
PBA showed similar potency, reducing the HDAC activity elicited by 10 µg HeLa extract to 
30% of the control value (Figure 21, red diamond and blue circle, respectively). Previously, I 
observed that the PTBA analog, 4-(phenylsulfonyl)butanoic acid (PSOBA), demonstrated no 
ability to expand renal progenitor cells (Figure 14C). Therefore, I hypothesized that it would 
function poorly in vitro as an HDACi. As expected, 5 mM PSOBA decreased the HDAC activity 
elicited by 10 µg HeLa extract to only 70% of the control value (Figure 21, green square). 
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Figure 19. PBA elicits concentration-dependent effects on larval edema and survival. (A 
through D) Embryos were treated with 0 to 30 µM PBA from 2 hpf, and larvae were scored 
at 72 hpf using a phenotype-based classification system (see Chapter 2 Methods). (A) Wild-
type (WT). (B) Edemic 1 (E1). (C) Edemic 2 (E2). (D) Graph of phenotypes after treatment 
with 0 to 30 µM PBA (n = 90 per concentration). Asterisk denotes lowest PBA concentration 
that exhibits a significant effect (p < 0.05) on survival. 
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Figure 20. TSA elicits concentration-dependent effects on larval edema and survival. (A 
through D) Embryos were treated with 0 to 300 nM TSA from 2 hpf, and larvae were scored 
at 72 hpf using a phenotype-based classification system (see Chapter 2 Methods). (A) Wild-
type (WT). (B) Edemic 1 (E1). (C) Edemic 2 (E2). (D) Edemic 3 (E3). (E) Graph of 
phenotypes after treatment with 0 to 300 nM PBA (n = 90 per concentration). Asterisk 
denotes lowest TSA concentration that exhibits a significant effect (p < 0.05) on survival. 
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Figure 21. PTBA functions as an HDACi in vitro. Fluorescence histone deacetylation assay 
performed in the presence of 5 mM PTBA, 5 mM PBA, 5 mM PSOBA, 1 µM TSA, or 5% 
DMSO. At a given amount of nuclear extract, less fluorescence indicates less HDAC 
activity. Error bars represent the 95% confidence intervals for each data point. 
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3.2.5 PTBA functions as an HDACi in vivo 
I next sought to determine whether the HDACi function of PTBA was quantifiable in vivo. I 
treated 24 hpf embryos with 3 µM PTBA, 25 µM PBA, or 200 nM TSA for 6 hours. Protein 
extracts were prepared and immunoblotted with an anti-hyperacetylated histone H4 antibody. 
Histone H4 hyperacetylation was observed following treatment with all three compounds at their 
tested concentrations, as compared with the control (Figure 22). Furthermore, increasing the 
compound concentration caused a corresponding increase in hyperacetylation (Figure 22). 
Therefore, both in vitro and in vivo results confirm that PTBA functions as an HDACi. 
 
 
Figure 22. PTBA functions as an HDACi in vivo. Western blot examining the acetylation 
state of histone H4 isolated from embryos at 30 hpf that had been treated for 6 hours with 
0.5% DMSO, 3 µM (1X) or 15 µM (5X) PTBA, 25 µM (1X) or 125 µM (5X) PBA, and 200 
nM (1X) or 1 µM (5X) TSA. Western blot for α-tubulin demonstrates equal loading.  
3.2.6 PTBA affects retinoic acid signaling 
HDACis are believed to lower the threshold of RA necessary to activate transcription.62 If PTBA 
treatment facilitates activation of the RA pathway, then expression of genes responsive to RA 
signaling should change. Consequently, I focused on two genes: cyp26a1, which is directly 
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activated by RA signaling,150 and the cardiac gene cmlc2, whose expression in the heart field size 
is reduced by RA treatments.151 In the previous study, cmlc2 expression was assessed for RA-
dependent effects in 18-somite embryos,151 therefore embryos were collected at the 18-somite 
stage for continuity. As compared to controls (n = 58), expression of cyp26a1 was increased in 
100% of PTBA-treated embryos (n = 57) (Figure 23, A and B). In agreement with this result, 
cmlc2 expression was decreased in 100% of PTBA-treated embryos (n = 58), as compared to 
controls (n = 57) (Figure 23, C and D).  
 
 
Figure 23. PTBA affects the expression of RA-responsive genes. (A through D) In situ 
hybridization for cyp26a1 (A and B) and cmlc2 (C and D) in 18-somite embryos treated with 
0.5% DMSO (A and C) or 3 µM PTBA (B and D). Arrowheads highlight cyp26a1 
expression domains. 
  
To provide a stronger link between PTBA treatment and RA signaling, mRNA encoding 
a dominant-negative RARα construct (DN-RARα), which is known to block RA signaling,152 
was injected prior to PTBA treatment. I performed in situ hybridization to determine the 
maximum amount of DN-RARα mRNA that could be injected at the one-cell stage without 
affecting lhx1a expression. In the tested range of 0 to 400 ng, embryos injected with 200 ng DN-
RARα mRNA or less showed normal lhx1a expression, while higher doses caused aberrant or 
decreased expression (data not shown). Therefore, I chose to inject 200 ng DN-RARα mRNA to 
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assess the relationship between PTBA and the RA pathway. As compared with controls (n = 80), 
I observed an expansion of lhx1a expression in 90% of the mock-injected PTBA-treated embryos 
at the 10-somite stage (n = 78) (Figure 24, A and B). Expression of lhx1a appeared normal in 
92% of embryos injected with 200 pg DN-RARα mRNA (n = 125) (Figure 24C). However, 
only 19% of the embryos injected with 200 pg DN-RARα mRNA and subsequently treated with 
PTBA showed expanded lhx1a expression (n = 125) (Figure 24D). Therefore, these data suggest 
that PTBA-mediated expansion of renal progenitor cells is dependent on the retinoic acid 
pathway. 
 
 
Figure 24. RA signaling mediates PTBA efficacy. (A through D) In situ hybridization in 10-
somite embryos mock-injected with 1% fluorescein dextran (A and B) or injected with 200 
pg of DN-RARα mRNA and 1% fluorescein dextran (C and D). At 5 hpf, embryos were 
treated with 0.5% DMSO (A and C) or 3 µM PTBA (B and D). 
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3.3 METHODS 
3.3.1 Zebrafish husbandry 
Zebrafish husbandry was performed as described in Chapter 2. 
3.3.2 Compound sources and treatments 
PTBA and methyl-4-(phenylthio)butanoate were synthesized as described in Chapter 2. 4-
(Naphthalen-2-ylthio)butanoic acid (NSC2733), 3-(phenylthio)benzoic acid (NSC113994), and 
2-amino-PTBA (NSC140113) were obtained from the NCI/DTP Open Repository. PBA, TSA, 4-
phenoxybutanoic acid, and 5-phenylpentanoic acid were obtained from Sigma-Aldrich. PSOBA 
was obtained from Matrix Scientific. Treatments were performed as described in Chapter 2, 
except for the in vivo hyperacetylation assays and DN-RARα experiments (see below).  
3.3.3 In situ hybridization 
In situ hybridization was performed as described in Chapter 2. 
3.3.4 Histone hyperacetylation assays 
SDS-PAGE and Western blotting were performed as described previously with some 
modifications.148 Proteins were separated on 18% SDS-PAGE gels. Membranes were incubated 
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at 4 oC overnight with 1:1000 anti-hyperacetylated histone H4 antibody (06-946, Millipore) or 
1:1000 anti-α-tubulin antibody (Sigma-Aldrich) in PBT containing 5% nonfat milk. 
3.3.5 Fluorescence HDAC assays 
In vitro HDAC activity assays were performed using a fluorescence HDAC assay kit (Active 
Motif) according to the manufacturer's instructions. For maintaining compound solubility at 5 
mM, the final DMSO concentration in all assay wells was increased to 5%. Fluorescence was 
detected using an M5 Plate Reader (Molecular Dynamics) 
3.3.6 mRNA synthesis and microinjections 
Synthetic mRNA was generated from the XRARα1405/pCD61 construct152 (NotI digested) using 
a T7 mMessage mMachine kit (Ambion). Zebrafish embryos were injected at the one-cell stage 
either with 200 pg of synthetic mRNA and 1% fluorescein dextran (Sigma-Aldrich) or with 1% 
fluorescein dextran alone (mock) and allowed to develop in E3 culture medium at 28.5 oC. At the 
256-cell stage, only fluorescein-dextran positive embryos were selected for PTBA treatment, 
which occurred at 5 hpf.  
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4.0  DEVELOPMENT OF PTBA ANALOGS 
4.1 HYPOTHESIS 
My previous work determined that treating zebrafish embryos with PTBA, a novel HDACi, 
increased the number of renal progenitor cells. Significantly, this led to a corresponding increase 
in pronephric size, suggesting that these cells are capable of contributing to nephrogenesis. As 
early as 1989, Bacallo and Fine proposed that kidney regeneration follows the same pattern of 
differentiation events that lead to nephrogenesis.153 Both processes begin with the proliferation 
of renal progenitor cells to provide the raw material necessary for subsequent differentiation into 
kidney tissue.153 Since PTBA stimulates renal progenitor cell proliferation during pronephric 
development, it may function similarly during kidney regeneration. However, developing PTBA 
into a potential therapeutic requires the consideration of both its efficacy and toxicity. 
Furthermore, expanding the structure-activity relationship study to a wider selection of small 
molecules may yield better candidates for future in vivo studies. Therefore, I chose to evaluate a 
panel of structural and functional analogs of PTBA to identify compounds exhibiting nanomolar 
efficacy and low toxicity in kidney cell culture. I hypothesized that modifying the key structural 
elements that determine the HDACi activity of PTBA would improve its ability to expand renal 
progenitor cells.   
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4.2 RESULTS 
4.2.1 Phenotypic screening of PTBA analogs 
As I have previously shown, treating zebrafish embryos with 3 µM PTBA generates pericardial 
edema by 72 hpf (Figure 4). This PTBA concentration also stimulates the proliferation of renal 
progenitor cells during pronephric development (Figures 6 and 12). Furthermore, by 48 hpf, 
embryos treated with 3 µM PTBA exhibit wider pronephric tubules and a failure of wt1a 
convergence at the dorsal midline (Figures 8, 9, and 10) Therefore, it is reasonable to 
hypothesize that the edemic phenotype reflects aberrant kidney morphogenesis resulting from an 
overabundance of renal progenitor cells. Consequently, I performed a phenotypic screen on a 
panel of PTBA analogs at 3 µM to identify potentially effective compounds. 
 Each of the compounds chosen for analysis represents either a structural or functional 
analog of the lead compound, PTBA. The structural analogs contain functional group additions 
or substitutions in one of four elements of the PTBA structure. These modify the key 
determinants of HDACi activity as predicted by the general pharmacophore: the aliphatic cap, 
connecting unit, hydrophobic linker, and zinc-binding group (Table 1). The structural analogs 
selected for the panel each contain one or more of these modifications (Table 1). Several 
functional group choices were based on previous structure-activity relationship studies of PTBA. 
For example, methylating the zinc-binding group of PTBA generated a compound equally 
capable of expanding lhx1a expression in treated embryos (Figure 14I). Therefore, the efficacy 
of several alkylated analogs was assessed.  
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Table 1. Structural analogs of PTBA. (Top left) General structure of the HDACi 
pharmacophore containing an aliphatic or aromatic cap (CAP), connecting unit (U), 
hydrophobic linker (LINKER), and zinc-binding group (ZBG). (Top right) General structure 
of a PTBA analog containing functional group substitutions as described in the table below.  
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In addition, I observed that the hydroxamic acid HDACi, trichostatin A (TSA), exhibited 
high efficacy, increasing lhx1a expression at 200 nM. (Figure 17D). Hydroxamic acids, which 
form two coordinate bonds with the active site zinc, are generally stronger than carboxylic acids, 
including PTBA, which form only one.154 Thus, several of the analogs tested contained 
hydroxamate moieties on the zinc-binding group.  
  Ten functional analogs were also chosen to represent a subset of known HDACis of 
several different classes (Figure 25). These include inhibitors derived from carboxylic acids, 
hydroxamic acids, benzamides, and natural products.155 With the exception of butanoic acid, all 
of the chosen compounds have predicted octanol-water partition coefficients (LogPs) greater 
than 1 (Appendix A). LogP indicates the hydrophobicity of a given molecule, with lipophilic 
compounds exhibiting higher values.156,157 Previous work determined that zebrafish embryos 
absorb compounds with logP values between 1 and 12 from embryo medium.116,158 
 The 32 compounds and a DMSO control were examined for their ability to generate 
pericardial edema in zebrafish larvae by 72 hpf (Table 2). Treatment with 12 compounds did not 
cause a statistically-significant decrease in the number of wild-type larval phenotypes, as 
compared with controls. This group included the four compounds containing connecting unit 
substitutions, seven of the known HDACis, and one alkylated analog, tert-butyl 4-
(phenylthio)butanoate. Treatment with each of the remaining analogs generated edemic and/or 
lethal phenotypes that were scored using the phenotype-based classification system from Chapter 
2. Three of these compounds, TSA, valproic acid, and apicidin, are known HDAC inhibitors. The 
lethality of 3 µM TSA was expected, since I previously demonstrated that 300 nM TSA killed 
greater than 90% of treated 72 hpf larvae (Figure 20).  
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Figure 25. Functional analogs of PTBA. (A through J) Structures of the HDACis butanoic 
acid (A), valproic acid (B), 4-phenylbutanoic acid (PBA, C), trichostatin A (TSA, D), SAHA 
(E), APHA compound 8 (F), Scriptaid (G), MS-275 (H), apicidin (I), and tubacin (J).  
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Table 2. Phenotypes observed in larvae treated with PTBA analogs. Embryos were treated 
with each compound at 3 µM from 2 hpf, and larvae were scored at 72 hpf using a 
phenotype-based classification system (Chapter 2). Compounds below the indicated line 
exhibit a significant decrease (p < 0.05) in the occurrence of wild-type phenotypes as 
determined by Fisher's exact test.  
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 Furthermore, with the exception of apicidin, all of the compounds that cause more severe 
phenotypes than PTBA contain either hydroxamic or alkylated zinc-binding groups. Taken 
together, these results suggest that modifications of PTBA anticipated to alter its underlying 
HDACi function may affect compound efficacy during pronephric development. However, 
pericardial edema can develop as a result of organ dysfunction unrelated to the kidney.159-161 
Therefore, I determined the effect of each of these compounds, if any, on renal progenitor cells. 
 To accomplish this, I examined lhx1a expression in treated embryos at the 10-somite 
stage. I performed in situ hybridizations on embryos treated with decreasing concentrations of 
compound, beginning at 3 µM (Table 3, raw data in Appendix B). The results were categorized 
relative to the efficacy of PTBA at a given concentration and are detailed below.   
4.2.2 PTBA analog efficacy in renal progenitor cells at 3 µM 
 Of the 12 compounds that exhibited no significant effect on larval phenotype, 10 
compounds did not expand lhx1a expression as compared with controls (no expansion, n = 36) 
(Tables 2 and 3). This group includes HDACis, such as SAHA and tubacin, which exhibit 
similar potency to TSA in vitro.162 However, treatment with 3 µM Scriptaid or tert-butyl 4-
(phenylthio)butanoate increased lhx1a expression in 39% and 25% of the tested embryos (n = 36 
each), respectively, as compared with controls (no expansion, n = 36) (Figure 26, A, C, and E). 
Therefore, the failure to develop pericardial edema following treatment is a predictive, but not 
absolute, indicator of an ineffective analog. 
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Table 3. Lhx1a expansion caused by analog treatment. In situ hybridization for lhx1a 
expression in 10-somite embryos treated from 2 hpf with each compound at the listed 
concentration. Analogs were classified according to their ability to increase lhx1a expression 
as effective (+), partially effective (+/-), or ineffective (-). Analogs that killed all embryos 
at a given concentration before reaching 10 somites are listed as XX. If the efficacy of a 
compound was not determined at a given concentration it is listed as ND. Note1: embryos 
surviving treatment with 800 nM apicidin (31%, n = 36) displayed general toxicity 
precluding efficacy scoring. Raw data are listed in Appendix B.   
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Figure 26. PTBA analogs exhibiting partial efficacy at 3 µM. (A through F) In situ 
hybridization for lhx1a expression in 10-somite embryos treated from 2 hpf with 0.5% 
DMSO (A) or 3 µM of the following compounds: valproic acid (20% expansion) (B), 
Scriptaid (25% expansion) (C), N-hydroxy-4-[(4-methoxyphenyl)thio]butanamide (31% 
expansion) (D), tert-butyl 4-(phenylthio)butanoate (39% expansion) (E), and methyl 4-
[(bromophenyl)thio]butanoate (74% expansion) (F).  
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Lhx1a expression analysis separated the 20 compounds, including PTBA, which caused 
edemic or lethal phenotypes into four groups. The first group, consisting of 4-(napthalen-2-
ylthio)butanoic acid and 3-(phenylthio) benzoic acid, caused no expansion of lhx1a in the treated  
embryos (Table 3). Therefore, their edemic phenotypes probably result from non-kidney related 
effects during embryonic development.  
 The second group, consisting of three compounds, expanded lhx1a expression in less than 
75% of the treated embryos in comparison to controls (Figure 26A). This group included 
valproic acid, a known HDACi, (20% expansion, n = 35), N-hydroxy-4-[(4-methoxyphenyl)thio] 
butanamide (31% expansion, n = 35), and methyl 4-[(bromophenyl)thio]butanoate (74% 
expansion, n = 35) (Figure 26, B, D, and F).  
The third group consisted of 12 effective compounds, including PTBA, that expanded 
lhx1a expression in greater than 90% of the treated embryos as compared with controls (Table 
3). The eleven PTBA analogs all contained either hydroxamic or alkylated zinc-binding groups. 
Compounds with these structural motifs also caused the most edema and lethality in the 
phenotypic screen (Table 2). Furthermore, all compounds showing greater than 90% efficacy by 
in situ hybridization demonstrate phenotypic effects similar to or more severe than those caused 
by PTBA (Tables 2 and 3). Therefore, the severity of edemic phenotypes does appear to 
correlate with the ability of a given PTBA analog to expand renal progenitor cells with some 
exceptions as previously noted. These compounds were subsequently tested to determine their 
efficacies at sequentially lower concentrations.  
 The final group, consisting of methyl 4-[(4-fluorophenyl)thio)]butanoate, apicidin, and 
trichostatin A, killed all treated embryos before they reached the 10-somite stage (Table 3). 
Toxicity of these compounds at 3 µM does not preclude them from expanding renal progenitor 
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cells at lower concentrations. Indeed, I previously observed that treating embryos with 200 nM 
TSA expands lhx1a expression in a manner similar to 3 µM PTBA (Figure 17D compared with 
Figure 5B). Therefore, the efficacy of these compounds at concentrations below 3 µM was 
assessed along with the previous group. 
4.2.3 PTBA analog efficacy in renal progenitor cells at 1.5 µM 
Two compounds, apicidin and TSA, were lethal at 1.5 µM, while 13 others demonstrated some 
ability to expand lhx1a expression in 10-somite embryos. Two of these were partially effective, 
expanding less than 75% of the treated embryos when compared with controls (no expansion, n = 
36) (Figure 27A). These were 4-[(bromophenyl)thio]-N-hydroxybutanamide (47% expansion, n 
= 36) and methyl 4-[(4-chlorophenyl)thio]butanoate (72% expansion, n = 36) (Figure 27, B and 
C). Because they lacked the efficacy of the remaining analogs, these compounds were not 
evaluated further.  
 Eleven compounds, including PTBA (83% expansion, n = 35) (Figure 27D), showed 
efficacy in greater than 80% of the treated embryos. Four contained hydroxamic zinc-binding 
groups, with three of these also carrying a substituted aliphatic cap: N-hydroxy-4-
(phenylthio)butanamide (92% expansion, n = 36), N-hydroxy-4-[(4-methylphenyl)thio] 
butanamide (97% expansion, n = 33), 4-[(4-chlorophenyl)thio]-N-hydroxybutanamide (97% 
expansion, n = 36), and 4-[(4-fluorophenyl)thio]-N-hydroxybutanamide (100% expansion, n = 
36) (Figure 27, E through H). 
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Figure 27. PTBA analogs exhibiting efficacy at 1.5 µM. (A through N) In situ hybridization 
for lhx1a expression in 10-somite embryos treated from 2 hpf with 0.5% DMSO (A) or 1.5 
µM of the following compounds: 4-[(bromophenyl)thio]-N-hydroxybutanamide (47% 
expansion) (B), 4-[(4-chlorophenyl)thio]butanoate (72% expansion) (C), PTBA (83% 
expansion) (D),  N-hydroxy-4-(phenylthio)butanamide (92% expansion) (E) , N-hydroxy-4-
[(4-methylphenyl)thio]butanamide (97% expansion) (F), 4-[(4-chlorophenyl)thio]-N-
hydroxybutanamide (97% expansion) (G), 4-[(4-fluorophenyl)thio]-N-hydroxybutanamide 
(100% expansion, n = 36) (H), methyl-4-(phenylthio)butanoate (89% expansion) (I), methyl 
4-[(4-methoxyphenyl)thio]butanoate (91% expansion) (J), methyl 4-[(4-methylphenyl)thio] 
butanoate (100% expansion) (K), methyl 4-[(4-fluorophenyl)thio]butanoate (100% 
expansion) (L), propyl 4-(phenylthio)butanoate (89% expansion) (M), and butan-2-yl 4-
(phenylthio)butanoate (89% expansion) (N). 
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 Four analogs had methylated zinc-binding groups, with three of these also including 
aliphatic cap substitutions: methyl-4-(phenylthio)butanoate (89% expansion, n = 36), methyl 4-
[(4-methoxyphenyl)thio]butanoate (91% expansion, n = 35), methyl 4-[(4-methylphenyl)thio] 
butanoate (100% expansion, n = 36), and methyl 4-[(4-fluorophenyl)thio]butanoate (100% 
expansion, n = 30) (Figure 27, I through L). The remaining two analogs demonstrating over 
80% efficacy carried propyl- and sec-butyl substitutions, respectively, on their zinc-binding 
groups: propyl 4-(phenylthio)butanoate (89% expansion, n = 36) and butan-2-yl 4-
(phenylthio)butanoate (89% expansion, n = 35) (Figure 27, M and N). Because each of these 10 
PTBA analogs exhibited efficacy above that of PTBA, these data support the approach of 
targeting motifs important in HDACi activity.  
4.2.4  PTBA analog efficacy on renal progenitor cells at 800 nM 
Treatments at 800 nM revealed two distinct groups of analogs based on efficacy. The partially 
effective compounds, consisting of PTBA and five analogs, expanded lhx1a expression in less 
than 25% of treated 10-somite embryos as compared with controls (Table 3). With the exception 
of 4-[(4-chlorophenyl)thio]-N-hydroxybutanamide, none of these compounds carried a 
substituted aliphatic cap. Because of their already limited efficacy at 800 nM, these compounds 
were not tested at lower concentrations. The five members of the more effective second group 
increased lhx1a expression in greater than 45% of treated embryos as compared with controls (no 
expansion, n = 36) (Figure 28A). This group of analogs included methyl 4-
[(methylphenyl)thio]butanoate (49% expansion, n = 35), methyl 4-[(methoxyphenyl)thio] 
butanoate (57% expansion, n = 35), 4-[(4-fluorophenyl)thio]-N-hydroxybutanamide (60% 
expansion, n = 35), N-hydroxy-4[(methylphenyl)thio]butanamide (61% expansion, n = 36) and  
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Figure 28. PTBA analogs exhibiting efficacy at 800 nM. (A through F) In situ hybridization 
for lhx1a expression in 10-somite embryos treated from 2 hpf with 0.5% DMSO (A) or 800 
nM of the following compounds: methyl 4-[(methylphenyl)thio]butanoate (49% expansion) 
(B), methyl 4-[(methoxyphenyl)thio]butanoate (57% expansion) (C), 4-[(4-
fluorophenyl)thio]-N-hydroxybutanamide (60% expansion) (D), N-hydroxy-
4[(methylphenyl)thio]butanamide (61% expansion) (E), and methyl 4-[(4-fluorophenyl)thio] 
butanoate (64% expansion, n = 36) (F). 
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methyl 4-[(4-fluorophenyl)thio]butanoate (64% expansion, n = 36) (Figure 28, B through F). 
Each of these compounds contained substitutions in both the zinc-binding group and aliphatic 
cap. These substitutions represented only a limited selection of functional groups. The zinc-
binding groups contained either hydroxamic acids or methylated carboxylic acids, while the 
aliphatic caps carried either methyl-, methoxy-, or fluoro- substitutions. These results suggest 
that certain structural motifs impart improved efficacy to the PTBA backbone.  
 Treatment with 800 nM apicidin killed 69% of the treated embryos (n = 36) (Table 3). 
Surviving embryos exhibited general toxicity that precluded the scoring of lhx1a expansion (data 
not shown). TSA treatment at 800 nM was lethal (Table 3). The five analogs exhibiting greater 
than 45% efficacy, apicidin, and TSA were retested at 400 nM.   
4.2.5 PTBA analog efficacy on renal progenitor cells at 400 nM or below 
Three of the five remaining structural analogs of PTBA and apicidin exhibited a partial ability to 
expand lhx1a expression at 400 nM in comparison to controls (n = 35) (Figure 29A). Of these, 
400 nM 4-[(4-fluorophenyl)thio]-N-hydroxybutanamide expanded 35% of treated embryos (n = 
34), the highest percentage of any tested PTBA structural analog at this concentration (Figure 
29B). Two others, methyl 4-[(methoxyphenyl)thio]butanoate (29% expansion, n = 35) (Figure 
29C) and methyl 4-[(4-fluorophenyl)thio]butanoate (26% expansion, n = 35), increased lhx1a 
expression in over 25% of treated embryos. Furthermore, methyl 4-[(4-
fluorophenyl)thio]butanoate also caused partial lhx1a expansion at 200 nM (22% expansion, n = 
32) (Figure 29D), while the other two structural analogs were ineffective (Table 3). This 
represents the lowest observed concentration of a structural PTBA analog capable of expanding 
renal progenitor cells.  
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Figure 29. PTBA analogs exhibiting efficacy at or below 400 nM. (A through F) In situ 
hybridization for lhx1a expression in 10-somite embryos treated from 2 hpf with 0.5% 
DMSO (A) or concentrations of the following compounds as indicated: 400 nM 4-[(4-
fluorophenyl)thio]-N-hydroxybutanamide (35% expansion) (B), 400 nM methyl 4-
[(methoxyphenyl)thio]butanoate (29% expansion) (C), 200 nM methyl 4-[(4-fluorophenyl) 
thio]butanoate (26% expansion) (D), 400 nM apicidin (22% expansion) (E), and 100 nM 
TSA (97% expansion) (F).  
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 Treatment with 400 nM apicidin expanded 22% of treated embryos (n = 36) (Figure 
29E), but was ineffective at 200 nM. All embryos treated with 400 nM trichostatin A died before 
reaching 10 somites (Table 3). However, treatment with 200 nM TSA caused lhx1a expansion in 
100% of treated embryos as compared with controls (n = 29) (Table 3). This observation is in 
agreement with my previous results (Figure 17D). Treatment with 100 nM TSA was also 
effective (97% expansion, n = 35), marking the lowest tested concentration of any PTBA analog, 
structural or functional, affecting renal progenitor cells (Figure 29F).   
4.2.6 Toxicity assays 
The cytotoxicity of the 15 compounds exhibiting efficacy or lethality at 3 µM was tested by 
collaborators, Drs. Lori Emert-Sedlak and Tom Smithgall of the Department of Microbiology 
and Molecular Genetics, in a conditionally-immortalized mouse podocyte cell line. Podocytes 
are polarized epithelial cells located on the glomerular basement membrane that contribute to the 
integrity of the filtration barrier.5 For the purposes of these experiments, they function as an 
indicator of renal toxicity. Following 72 hours of treatment with each compound concentrations 
ranging from 30 µM to 3 nM, podocyte viability was assessed by measuring residual metabolic 
activity (Figure 30, raw data in Appendix C). From these data, Dr. Emert-Sedlak calculated the 
concentration where 50% of the exposed podocytes remained viable (E50). Of the 15 analogs 
tested, only two, TSA and apicidin, caused sufficient cytotoxicity to allow the calculation of an 
E50 value. Over the course of three experiments, TSA exhibited a mean E50 of 96 nM (s = 51 
nM), while the mean E50 for apicidin was 152 nM (s = 54 nM). Treatment with PTBA or each of 
12 structural analogs never decreased podocyte viability below the 50% threshold, even when 
tested at 30 µM (Figure 30). In fact, over three experiments, podocyte viability never dropped 
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below 80% following treatment with any of these compounds. Therefore, PTBA analogs 
carrying cap and/or zinc-binding group modifications, do not increase the toxicity of the 
compound relative to PTBA.  These results suggest that the efficacy of PTBA can be improved 
through analog development without causing a corresponding increase in compound toxicity.  
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Figure 30. Structural PTBA analogs exhibit low toxicity in cultured podocytes. Podocytes 
were treated for 72 hours with 30 µM, 10 µM, 1 µM, 300 nM, 100 nM, 30 nM, 10 nM, or 3 
nM of each compound or a DMSO control. Viability was assessed using Cell Titer-Blue. 
Viability was calculated as a percentage of the DMSO control, which was considered 100% 
viability. Data represent the average results of three independent experiments using duplicate 
wells for each condition.   
 
 77 
4.3 METHODS 
4.3.1 Zebrafish husbandry 
Zebrafish husbandry was performed as described in Chapter 2 
4.3.2 Compound sources and treatments 
PTBA and methyl-4-(phenylthio)butanoate were synthesized as described in Chapter 2. 4-
(Naphthalen-2-ylthio)butanoic acid (NSC2733) and 3-(phenylthio)benzoic acid (NSC113994), 
were obtained from the NCI/DTP Open Repository. APHA compound 8, Apicidin, butanoic 
acid, PBA, 4-phenoxybutanoic acid, 5-phenylpentanoic acid, Scriptaid, TSA, and valproic acid 
were obtained from Sigma-Aldrich. MS-275 and SAHA were obtained from Cayman Chemical 
Co. 4-(phenylsulfonyl)butanoic acid was obtained from Matrix Scientific. Tubacin was a gift of 
Dr. Ralph Mazitschek of the Broad Institute (Cambridge, MA). The remaining PTBA analogs 
were synthesized by Dr. Vasiliy Korotchenko of the Department of Pharmaceutical Sciences. 
Three independent groups of 12 chorionated 2 hpf embryos were arrayed in individual wells of 
24-well plates. E3 medium was removed with a glass pipette and replaced with 800 µl treatment 
solutions containing 0.5% DMSO in E3 with or without compound at the reported 
concentrations.  
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4.3.3 In situ hybridization 
In situ hybridization for lhx1a was performed as described in Chapter 2. Embryos were 
considered expanded if they exhibited lhx1a expression consistent with that resulting from 
treatment with 3 µM PTBA. Compounds were classified as effective, partially-effective, or 
ineffective based on comparison to the effects of PTBA at a given concentration.  
4.3.4 Phenotypic screening 
Phenotypic screening of PTBA analogs was performed identically to the concentration-response 
experiments detailed in Chapter 2. Embryos were treated with each PTBA analog from 2 to 72 
hpf as described above.  
4.3.5 Podocyte cytotoxicity assays 
The conditionally-immortalized mouse podocyte cell line was a gift of Dr. Leslie 
Bruggeman of Case Western Reserve University (Cleveland, OH). The isolation and 
characterization of these cells have been previously described.163,164 Mouse podocytes were 
plated at a density of 6,000 cells per 200 µl in 96-well plates to elicit log-phase growth. The 
indicated PTBA analogs were added at 30 µM, 10 µM, 1 µM, 300 nM, 100 nM, 30 nM, or 3 nM 
and incubated at 33 oC for 72 hours. The final DMSO concentration was maintained at 0.2% in 
all treatments except 30 µM (0.6%). After incubation, cytotoxicity was analyzed using the Cell 
Titer-Blue Cell Viability Assay (Promega) per manufacturer's instructions. Reagent (20 µl) was 
added to 100 µl of cells and plates were incubated for 2 hours at 37 oC. Fluorescence was read at 
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560Ex/590Em on a Gemini SpectramaxXS (Molecular Devices) plate reader. Viability was 
calculated as a percentage of the DMSO control, which was considered 100% viability. Data 
represent the results of three independent experiments using duplicate wells for each condition. 
E50 values were determined from the transformed and normalized data by non-linear regression.        
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5.0  DISCUSSION 
5.1 LESSONS FROM SMALL MOLECULE SCREENING 
From a screen of almost 2000 small molecules, we identified a compound, PTBA, that had not 
been previously reported as a "hit" in 136 previous chemical library screens165. The success of 
our screen validates the use of an edemic phenotype as an indicator of aberrant kidney 
development. Furthermore, it emphasizes the importance of sound experimental design in 
determining the desired outcome. Many factors should be considered before beginning to 
interrogate libraries containing thousands of small molecules. Indeed, depending on the 
predetermined goals and parameters of the screen, investigators can generate completely 
different data sets using the same compound library.  
 To illustrate this point, consider the results of the chemical screens performed by my own 
lab and those of the neighboring Tsang lab.166,167 Both groups tested zebrafish embryos at 10 µM 
using NCI/DTP Diversity Set compounds drawn from daughter plates derived from the same 
DMSO stocks. Furthermore, each lab identified a compound, PTBA or BCI, that expanded 
progenitor cells, leading to increased kidney or heart size, respectively. However, the differing 
experimental approaches utilized by our groups masked the effects of the other small molecule. 
The Tsang lab identified BCI by treating transgenic embryos carrying a fluorescent FGF-
signaling reporter from 24 to 32 hpf. Since PTBA loses efficacy at about 15 hpf and edema 
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typically does not develop until at least 48 hpf, PTBA-treated embryos would appear wild-type. 
Therefore, even if they had recorded interesting secondary phenotypes beyond those involved in 
FGF signaling, PTBA would have been missed using this approach. Likewise, BCI-treated 72 
hpf larvae were scored as wild-type in our phenotypic screen, even though they almost certainly 
contained enlarged hearts. Although both screens were ultimately successful, their unique 
observations depended on the selection of treatment windows and phenotypes appropriate for the 
research. Without these considerations, the effects of interesting small molecules can be easily 
overlooked.  
Another important factor contributing to the discovery of PTBA was the concentration 
chosen for the screen. In this, we were very fortunate. All compounds were ostensibly tested at 
10 µM in embryo medium. Had this truly been the case, then my data suggests that PTBA 
treatment would have killed all the embryos before reaching 72 hpf. Since we performed no 
further characterization on compounds found to be lethal at the screening concentration, PTBA 
might never have been characterized. Luckily, compound concentrations in DMSO stocks can 
vary several fold from the reported value in small molecule libraries.131 Thus, the concentration 
in the PTBA-containing well was probably much closer to 3-5 µM, allowing edema formation 
and generating a positive hit. Furthermore, had we decided to screen at a lower concentration, the 
larvae may have appeared wild-type, again precluding any further testing. This exposes a flaw in 
the way many small molecule screens are performed: very few involve screening at multiple 
concentrations. It could be argued that repeated screening of a library is a waste of time and 
effort, especially if hits have been identified. However, small molecule libraries generally 
already represent a significant investment of resources, and follow-up screens at different 
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concentrations merit consideration. At the very least, compounds observed to be lethal in the 
initial screen could be retested at lower concentrations in search of relevant phenotypes. 
5.2 MODELING HOW PTBA ENGAGES THE RA PATHWAY 
Treating zebrafish embryos with PTBA stimulates RA signaling, as evidenced by its effects on 
the RA-responsive genes cyp26a1 and cmlc2. Consequently, blocking RA signaling at the 
receptor level with dominant-negative RARα greatly reduced PTBA efficacy. Therefore, PTBA 
likely interacts with some elements of the RA signaling pathway in order to stimulate renal 
progenitor cell proliferation during pronephric development. The characterization of PTBA as a 
novel HDACi suggests that the targets are most likely the HDACs controlling the repression of 
RA-responsive genes. 
In the absence of RA, an RAR/RXR dimer binds the RARE in regulated promoters and 
recruits complexes of corepressor proteins, including an HDAC (Figure 31A). The HDAC 
deacetylates nearby nucleosomes, causing chromatin condensation which inhibits gene 
transcription. When RA binds the RAR/RXR dimer, it elicits a conformational change that 
removes the HDAC from close proximity to the nucleosomes (Figure 31B). This facilitates the 
activity of coactivators, such as histone acetyltransferases, which decondense the chromatin and 
allow transcription to occur. By inhibiting the corepressor HDAC, HDACis have been 
hypothesized to lower the RA concentration necessary to activate the RAR/RXR dimer (Figure 
31C).62 In this way, PTBA could stimulate RA signaling at the receptor level without affecting 
the endogenous RA concentration. 
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Figure 31. HDACis enhance RA signaling. (A) In the absence of RA, RAR/RXR dimers 
recruit a corepressor complex (CoR) containing an HDAC. The HDAC deacetylates 
nucleosomes, causing chromatin condensation and preventing transcription. (B) In the 
presence of RA, the RAR/RXR dimer undergoes a conformational change, removing the 
HDAC from close association with nucleosomes. This allows coactivators such as a histone 
acetyltransferase (HAT) to acetylate the nucleosomes, which decondenses the chromatin and 
permits transcription. (C) HDAC inhibitors, such as PTBA, have been hypothesized to 
decrease the required concentration of RA necessary to trigger the RAR/RXR 
conformational switch. Figure adapted from Menegola and coworkers.62 
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The downstream target of RA-signaling that mediates the effects of PTBA on renal 
progenitor cells remains unknown. Since my results argue that PTBA treatment stimulates renal 
progenitor cell proliferation without significantly transforming juxtaposed tissues, the effect is 
probably local. Therefore, PTBA may enhance RA signaling directly within renal progenitor 
cells, leading to increased proliferation. Because attenuation does not require the synthesis of 
protein intermediates, this hypothesis is compatible with the previous work of Cartry and 
coworkers.63 They observed that treating Xenopus embryos with RA caused lhx1a expansion 
even in the presence of the protein synthesis inhibitor, cycloheximide.63 Furthermore, treating 
kidney epithelial cell lines with RA increased both thymidine uptake and the proportion of cells 
in S-phase.168,169 Therefore, it is possible that the proliferative machinery in renal progenitor cells 
may respond to RA-signaling in a similar manner. 
5.3 THERAPEUTIC POTENTIAL OF PTBA 
5.3.1 Proliferation: the intersection of development and regeneration 
In many respects, the process of kidney regeneration mimics that of nephrogenesis.153 In both 
cases, a multipotent cell first proliferates to provide the necessary raw material and then 
differentiates into the required tissue type. Several hypotheses have been proposed to explain the 
source of the multipotent cells involved in regeneration. The first, and most generally accepted, 
suggests that these cells arise from tissue dedifferentiation near the site of damage.170 Other 
groups argue that the multipotent cells are actually stem cells of intrarenal or extrarenal 
origin.171,172 In any case, it is reasonable to assume that these cells share elements in common 
 85 
with renal progenitor cells. Therefore, I hypothesize that they may also exhibit similar 
proliferation in response to PTBA treatment. 
This hypothesis may explain the observations made by other groups regarding the 
relationship between HDAC inhibition and renal regeneration. In one study, Imai and coworkers 
demonstrated that treating mice with daily injections of TSA attenuated renal damage following 
injury.173 Since PTBA and TSA both function as HDACis and expand renal progenitor cells, they 
may also act similarly in facilitating renal regeneration. In another study, Marumo and coworkers 
demonstrated that the expression of Hdac5 was significantly decreased following acute ischemic 
damage in mouse kidneys.174 This suggests that the reduction of HDAC activity may serve as an 
important part of the regeneration process. Therefore, at least some evidence supports the idea 
that PTBA may function as a useful therapeutic following acute kidney injury. 
5.3.2 Analog efficacy in a mouse model of acute kidney injury 
To test this hypothesis, we have been collaborating with Drs. Raymond Harris and Mark de 
Caestecker at Vanderbilt University. Dr. Harris' lab has developed a transgenic mouse model of 
acute kidney injury using diphtheria toxin (DT) as a nephrotoxic agent. Unlike humans, mice are 
normally resistant to DT exposure. This resistance arises from several amino acid differences in 
the protein acting as the DT receptor, heparin-binding EGF-like growth factor (Hbegf).175 
Transgenic mice (PTC-DTR) express human HBEGF in their proximal tubules, creating the 
conditions for an acute and specific damage event. 
Since blood is a buffered solution, testing PTBA would have been a poor choice. At 
neutral pH, the zinc-binding group would be deprotonated and the resulting polar charge would 
greatly decrease its absorption through cell membranes. Instead we tested an effective structural 
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analog carrying a methylated zinc-binding group, methyl 4-(phenylthio)butanoate (MPTB). 
PTC-DTR mice were injected with DT and damage was allowed to accrue for one day. At this 
time, mice were given daily injections of MPTB or a DMSO control for the next six days. 
Preliminary data from a single group of mice suggest that MPTB treatment significantly 
increases the rate of renal recovery by approximately 30% (Figure 32). Therefore, PTBA 
analogs demonstrate some promise as renal therapeutics following acute kidney injury. 
5.3.3 Factors governing the toxicity of PTBA analogs 
Toxicity is also an important consideration during the development of any drug. At its effective 
concentration, I observed that PTBA exhibits much milder effects on juxtaposed mesodermal 
tissues in comparison to TSA. Furthermore, structural PTBA analogs, even when administered at 
30 µM, demonstrated little effect on podocyte cell viability in cell culture assays. However, my 
data suggest that treating podocytes with 100 nM TSA would be expected to kill at least 50% of 
the cells within 72 hours. There are at least two possible explanations for this difference in 
toxicity, each reflecting different considerations of HDAC-HDACi binding.  
Crystallography studies have revealed how several HDACis block substrate access by 
interacting with the Zn2+ in the catalytic site of an HDAC. Therefore, most HDACis, including 
carboxylic and hydroxamic acids, function as competitive inhibitors of HDACs, although 
noncompetitive HDACis, such as Trapoxin A, have been characterized.176-179 In this example, 
taken from the Protein Data Bank, TSA occupies the binding site of human HDAC7 by 
coordinating its hydroxamic acid motif with the catalytic Zn2+ (Figure 33). In general, 
hydroxamic HDACis bind HDACs much more strongly than HDACis containing carboxylic acid  
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Figure 32. Treatment with MPTB increases the rate of renal recovery in mice following 
acute kidney injury. Female PTC-DTR mice were injected with 0.1 µg/kg DT on day 0. 
Beginning on day 1, mice were treated with daily injections of 1% DMSO or 3.4 mg/kg 
MPTB (n = 5 per group). Blood urea nitrogen (BUN), a biomarker of nitrogenous wastes, 
was determined every two days following DT injection. Error bars are the standard error of 
the mean. Asterisk represents a significant difference in BUN concentration (p < 0.002) as 
determined by t-test. Data generated by Mark de Caestecker. 
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Figure 33. Binding of TSA to human HDAC7 as determined by X-ray crystallography. (A) 
TSA co-crystallized with HDAC7 (ribbon model). (B) TSA co-crystallized with HDAC7 
(space-filling model). (C) Magnification of (B), showing coordination of the hydroxamic 
motif of TSA with the catalytic site Zn2+. Panels generated by Tom Smithgall from Protein 
Data Bank entry 3C10. 
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zinc-binding groups, such as PTBA.154 This is because PTBA should form only one coordinate 
bond with the active site zinc, an arrangement known as monodentate binding.154 In contrast, the 
hydroxamic acid of TSA binds in a bidentate fashion, forming two coordinate bonds with the 
active site zinc.154 This difference is reflected in the results of my in vitro HDAC analysis. I 
observed that TSA inhibited all HDAC activity at micromolar concentrations, while PTBA 
reduced HDAC activity by only 70% at millimolar concentrations. However, this large efficacy 
difference is not evident in vivo. PTBA and TSA were found to generate similar increases in 
histone hyperacetylation at concentrations within about one log of each other. These data suggest 
that additional factors may be involved in determining compound efficacy in the context of a 
whole organism.  
The difference in HDAC isoform specificity between carboxylic and hydroxamic acids 
may provide a possible explanation for these observations. HDAC isoforms are separated into 
four classes based on their size, homology, cellular localization, and catalytic activity (Figure 
34).180 For example, Class I isoforms generally exhibit nuclear localization, while Class II 
HDACs are primarily cytoplasmic.181 Carboxylic acid HDACis are considered to be specific 
inhibitors of Class I and IIa HDACs, while hydroxamic acids target Class I, II, and IV isoforms 
(Figure 34).180,182-184 Meanwhile, the Class III HDACs (sirtuins), utilize an NAD+-dependent 
catalysis mechanism that remains unaffected by carboxylic or hydroxamic HDACis (Figure 
34).185,186 Although the class specificity of PTBA has not yet been confirmed, it can be 
hypothesized to function as a Class I/IIa-specific inhibitor like other carboxylic acids. 
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Figure 34. HDAC classes inhibited by carboxylic and hydroxamic acid HDACis. Carboxylic 
acid HDACis: butanoic acid, valproic acid, PBA, and TSA. Hydroxamic acid HDACis: TSA 
and SAHA. Class I, II, and IV HDACs utilize Zn2+-dependent catalysis, while the Class III 
sirtuins employ an NAD+-dependent mechanism.  
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Several inferences can be made from these isoform specificities. First, if PTBA efficacy 
in zebrafish embryos does indeed require the inhibition of one or more HDAC isoforms, then  
hdacs 6, 10, and 11 are probably not targeted. Therefore, it is possible that the increased toxicity 
observed in TSA-treated embryos may result from its effect on these hdacs. Of particular interest 
is HDAC6, which functions as a microtubule-associated deacetylase.187 Affecting the post-
translational modifications of the microtubule network causes broad effects on cell signaling and 
the maintenance of homeostasis.187 However, embryos treated with tubacin, an HDAC6-specific 
HDACi,188 appeared wild-type in my phenotypic screens. It is possible that tubacin's LogP of 
6.34, the highest of any tested PTBA analog (Appendix A), may prevent efficient compound 
absorption and could account for the lack of phenotype.  
Furthermore, the broad specificity of hydroxamic HDACis suggested that hydroxamic 
PTBA analogs would demonstrate greater efficacy at the expense of increased toxicity. Indeed, 
several hydroxamic analogs increased lhx1a expression in treated embryos at concentrations 
equal to or less than PTBA. However, my data from zebrafish embryos and podocyte culture 
suggest that this modification has little to no effect on compound toxicity. This may imply that 
the hydroxamic analogs remain weak inhibitors despite the improved strength of the zinc-binding 
group. Accordingly, their HDACi activity should be determined empirically in future in vitro 
assays. Alternatively, the products generated from the metabolism of TSA may cause the 
deleterious effects observed in treated embryos. Indeed, some evidence suggests that the N-
demethylated byproducts of TSA remain pharmacologically active and persist in the circulation 
for at least an hour following administration.189 However, it is currently unknown if these 
metabolic waste products affect normal cellular processes.  
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5.3.4 HDACis are clinically relevant 
Previous clinical studies with known HDACis suggest that structural analogs of PTBA may 
function as viable therapeutics. Indeed, both trichostatin A (Vorinostat) and valproic acid have 
received U.S. Food and Drug Administration (FDA) approval for oral administration to treat T-
cell lymphoma and epilepsy, respectively.190 Importantly, the sodium salt of PBA (Buphenyl), 
one of the closest structural analogs of PTBA, also received FDA approval in 1996 for the 
treatment of urea cycle disorders.191 To date, Buphenyl remains the only FDA-approved 
treatment for chronic management of the excess blood ammonia (hyperammonemia) generated 
by enzymatic deficiencies in urea metabolism.192 Prescribed daily doses of Buphenyl as an oral 
medication often reach gram quantities, with some patients taking as much as 20 g/day.193 Thus, 
it may be possible to safely administer other PTBA analogs at similarly high doses. In addition, 
Buphenyl exhibits good bioavailability of about 80% when taken orally.194 Unfortunately, 
Buphenyl has a short half-life (t1/2 ~ 1 hr) following administration, as it is rapidly converted to 
phenylacetic acid.194 However, this limitation can be easily overcome by prescribing multiple 
daily dosings.194 Therefore, the favorable pharmacological properties of sodium PBA support the 
future development of other PTBA analogs for clinical use. 
5.4 IMPORTANT CONSIDERATIONS AND OPEN QUESTIONS 
Despite these encouraging results, several critiques must be considered to make a fair assessment 
of the contributions and future impact of this work. Although, the zebrafish pronephros serves as 
an excellent model of individual metanephric nephrons, metanephroi are complex organs 
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consisting of millions of nephrons. It is unknown how accurately simple pronephric models 
reflect conditions within the broader context of general metanephric kidney function. Future 
experiments with PTBA analogs in mouse models of kidney injury may help to address this 
concern. Furthermore, while my data suggest that PTBA treatment affects normal pronephric 
function, thus causing the edemic phenotype, this was not determined empirically. Although the 
pronephros is almost certainly nonfunctional at 48 hpf because the glomerulus has not yet 
formed, fluorescent dextran injections could provide further confirmation. Indeed, it would be 
interesting to determine if PTBA-treated embryos manage to form functional pronephroi later in 
development. 
My research provided some insight into the mechanism of PTBA efficacy, revealing the 
involvement of the RA signaling pathway and HDAC inhibition. However, the specific target of 
PTBA activity remains unknown. Ostensibly, this should be an HDAC isoform or isoforms, 
perhaps representing a specific HDAC class. However, it is important to note that HDACis 
modify many non-histone proteins in their capacity as lysine deacetylases.195 These targets 
include hormone receptors, signal transducers, transcriptions factors, structural proteins, and 
chaperones.195 Therefore, target identification may not be a straightforward prospect. However, I 
believe that an investigation of possible HDAC targets still represents the best place to start. My 
preliminary results suggest that the expression patterns of individual hdac isoforms remain 
relatively ubiquitous in 24 hpf zebrafish embryos (data not shown). It may be helpful to 
determine if any of these become compartmentalized in the pronephric region later in 
development. These isoforms would be good candidates as potential PTBA effectors. 
Furthermore, like other carboxylic acid HDACis, PTBA would be expected to exhibit some 
Class I/IIa specificity. If this characteristic is confirmed in future investigations, then isoforms of 
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these classes should also merit some interest. Morpholino knockdown of these candidates in an 
effort to recapitulate lhx1a expansion in the IM would provide an excellent approach for target 
validation. 
When developing potential human therapeutics using zebrafish, consideration should be 
given to the variation in HDAC orthologs across species. Although zebrafish hdacs, such as 
hdac1, share a large degree of amino acid identity with the HDACs of other vertebrates, 
discrepancies remain (Figure 35). These differences could alter the efficacy of PTBA or its 
analogs when applied in other model systems or in humans. Encouragingly, PTBA demonstrated 
the ability to function in vitro as an HDACi using human HDAC isoforms derived from HeLa 
cell extracts. However, this result does not eliminate the possibility of differing efficacies when 
assessing individual HDAC orthologs. 
 
 
Figure 35. Evolutionary relationship between HDAC1 orthologs in selected vertebrates. 
Cladogram generated using TreeView software (ver. 1.6.6) and HDAC1 RefSeq protein 
sequences for each species. Percentage denotes percent sequence identity with the human 
isoform. Scale bar represents nucleotide substitutions per site.  
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In addition to the points raised above, several other open questions remain unanswered. 
Potent HDACis, such as SAHA and MS-275, showed no effect on zebrafish embryos when they 
were treated at 3 µM. This was an unexpected result which could reflect poor absorption of the 
compounds into the embryos, short half-lives, or a zebrafish-specific effect. Hyperacetylation 
assays could be performed to determine if the compounds are indeed able to exert a 
physiological effect on embryos, despite the lack of edemic phenotype. Furthermore, exploring 
the downstream effects of HDAC inhibition, such as the stimulation of coactivators, would 
provide further confirmation of the mechanism of PTBA efficacy. For example, 
pharmacologically inhibiting the activity of histone acetyltransferases (HATs) would be expected 
to block PTBA efficacy by interfering with its signaling. One final point of interest is better 
understanding the differences in PTBA efficacy when compared to TSA in my in vitro and in 
vivo assays. In vitro, TSA is thousands of times more effective than PTBA in inhibiting HDAC 
activity, while in vivo the difference is greatly reduced. Of course, the varying HDAC class 
specificities of the two compounds may play a role in this effect. However, I suspect that the 
structural elements of PTBA, particularly the thiol group, may provide the compound with 
unique in vivo pharmacokinetics.  
5.5 NEXT GENERATION PTBA ANALOGS 
My results demonstrate that several PTBA analogs exhibit improved efficacy with little to no 
increase in toxicity. These second generation compounds are excellent candidates to improve 
renal recovery in future animal studies. However, I believe that my work marks only the first 
steps in the development of this family of compounds. Using only simple functional group 
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substitutions, I was able to identify PTBA structural analogs that were only several times less 
effective than TSA. However, these same analogs exhibit several hundred times less toxicity 
than TSA in podocyte cell culture. This represents the key benefit offered by this class of "weak" 
inhibitors. It is true that almost all of the effective PTBA analogs cause some degree of edemic 
and/or lethal phenotypes during zebrafish development. However, these teratogenic effects 
should not be an issue when treating an adult, whose tissues primarily consist of differentiated 
cells. Indeed, according to our collaborators, the PTC-DTR mice treated with MPTB exhibit no 
overt signs of toxicity (data not shown).  
Because the second generation PTBA analogs exhibit little toxicity, I believe that there is 
still ample room for further efficacy improvements. The results of my research offer some 
guidelines for this process. In general, substitutions of the aliphatic cap region increased 
compound efficacy. Adding functional groups to the phenyl ring represents a simple way to 
increase the LogP value of the base compound, which may aid absorption through biological 
membranes. Alternatively, the cap substitutions may interact with amino acids in the binding 
pocket of the HDAC, improving the affinity of the compound. Interestingly, even halogenated 
groups, which are often metabolized into toxic byproducts,196 appear to be tolerable. 
The sulfur atom forming the connecting unit of PTBA also appears to be a critical 
activity determinant. In comparison to its substituted analogs, I observed that only PTBA 
exhibited significant efficacy. Since the LogP values of PTBA and the analogs carrying 
connecting unit substitutions are similar, I doubt that improved absorption plays a role. More 
likely, the sulfur atom forms unique interactions within the HDAC binding pocket. This may 
include serving as a hydrogen bond acceptor due to the presence of an unbound electron pair. 
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Unfortunately, only one analog carrying a linker group was available for testing. Adding 
a bulky ring structure to the linker decreased the analog's efficacy relative to PTBA. The 
increased rigidity of the normally flexible hydrophobic chain may explain this effect. I believe 
that increasing the length of the linker region remains an untapped opportunity to generate a 
better analog. Indeed, the linkers of the more potent HDACis, including TSA and SAHA, contain 
seven and eight carbons respectively.  
Finally, I also observed that analogs carrying methylated or hydroxamic zinc-binding 
groups exhibit improved efficacy. Adding alkyl groups to the zinc-binding group might be 
expected to interfere with the formation of coordinate bonds with the active site zinc. However, 
it is likely that the ubiquitous esterases found in target cells hydrolyze and remove the alkyl 
groups upon absorption. Furthermore, since alkylation prevents deprotonization of the carboxylic 
acid, these analogs would be expected to be more effective in buffered solutions. The 
hydroxamic analogs of PTBA also demonstrated improved efficacy, although perhaps not as 
much as I had expected. Although they possess stronger zinc-binding groups, they suffer from 
increased polarity as evidenced by lower LogP values. Therefore, the expected increase in 
binding affinity may be counterbalanced by decreased absorption. Importantly, the hydroxamic 
PTBA analogs demonstrate none of the toxicity of TSA in cell culture experiments. Further 
modifications of these structures, perhaps incorporating some elements of the TSA structure, 
may yield a family of highly potent compounds. 
It is my sincere hope that this research forms the foundation for new therapeutic 
approaches to improve outcome following renal damage. Preliminary results show promise, and 
further investigations with subsequent generations of PTBA analogs are certainly warranted. 
Furthermore, my research suggests that we should not be so quick to dismiss compounds others 
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may consider weak or uninteresting. In 1979, PTBA and several analogs were first discussed as 
compounds with "expected biological activity."197 It required over thirty years and one graduate 
student's career to confirm this prediction. 
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APPENDIX A 
PARTITION COEFFICIENTS OF PTBA ANALOGS  
 
Table 4. Predicted octanol-water partition coefficients (XLogPs) of the PTBA analogs. 
XLogP values were calculated from the chemical structures using XLOGP3 (ver. 3.2.2), a 
web-based application available at http://www.sioc-ccbg.ac.cn/software/xlogp3/. 
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APPENDIX B 
PHENOTYPIC SCREENING OF PTBA ANALOGS 
 
Table 5. Raw data for Table 3. Data are lhx1a expanded/total embryos for each condition. 
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APPENDIX C 
PODOCYTE TOXICITY DATA 
 
Table 6. Toxicity of PTBA analogs in cultured podocytes (first replicate). Toxicity was 
assayed by CellTiter-Blue Cell Viability Assay. Values represent percentage of viable 
podocytes following 72 hours of treatment with each analog  at the listed concentration (see 
Chapter 4, Methods). These data were used to generate Figure 30. 
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Table 7. Toxicity of PTBA analogs in cultured podocytes (second replicate). Toxicity was 
assayed by CellTiter-Blue Cell Viability Assay. Values represent percentage of viable 
podocytes following 72 hours of treatment with each analog  at the listed concentration (see 
Chapter 4, Methods). These data were used to generate Figure 30. 
 
 
Table 8. Toxicity of PTBA analogs in cultured podocytes (third replicate). Toxicity was 
assayed by CellTiter-Blue Cell Viability Assay. Values represent percentage of viable 
podocytes following 72 hours of treatment with each analog  at the listed concentration (see 
Chapter 4, Methods). These data were used to generate Figure 30. 
 
 103 
BIBLIOGRAPHY 
1 Smith, H. W. From fish to philosopher: the story of our internal environment. Ciba 
edition, revised and enlarged edn,  (Ciba Pharmaceutical Products, Inc., Summit, NJ, 
1959). 
2 Rennke, H. G. & Denker, B. M. Renal pathophysiology: the essentials. 3rd edn,  
(Lippincott Williams & Wilkins, Philadelphia, PA, 2010). 
3 Eaton, D. C. & Pooler, J. P. Vander's renal physiology. 7th edn,  (McGraw-Hill Medical, 
New York, NY, 2009). 
4 Brenner, B. M., ed. Brenner & Rector's the kidney. 8th edn,  (Saunders Elsevier, 
Philadelphia, PA, 2008). 
5 Vize, P. D., Woolf, A. S. & Bard, J. B. L., eds. The kidney: from normal development to 
congenital disease.  (Academic Press, San Diego, CA, 2003). 
6 Brenner, B. M., Hostetter, T. H. & Humes, H. D. Glomerular permselectivity: barrier 
function based on discrimination of molecular size and charge. Am J Physiol 234, F455-
460, (1978). 
7 Sherwood, L. Fundamentals of physiology: a human perspective. 3rd edn,  (Thomson 
Brooks/Cole, Belmont, CA, 2006). 
8 Hoy, W. E. et al. Nephron number, glomerular volume, renal disease and hypertension. 
Curr Opin Nephrol Hypertens 17, 258-265, (2008). 
9 Zhou, W., Boucher, R. C., Bollig, F., Englert, C. & Hildebrandt, F. Characterization of 
mesonephric development and regeneration using transgenic zebrafish. Am J Physiol 
Renal Physiol, (2010). 
10 Saxen, L. Organogenesis of the kidney.  (Cambridge University Press, Cambridge, UK, 
1987). 
 104 
11 Jones, E. A. Xenopus: a prince among models for pronephric kidney development. J Am 
Soc Nephrol 16, 313-321, (2005). 
12 Drummond, I. A. The zebrafish pronephros: a genetic system for studies of kidney 
development. Pediatr Nephrol 14, 428-435, (2000). 
13 Mobjerg, N., Larsen, E. H. & Jespersen, A. Morphology of the kidney in larvae of Bufo 
viridis (Amphibia, Anura, Bufonidae). J Morphol 245, 177-195, (2000). 
14 Davidson, A. J. Mouse kidney development in StemBook (Harvard Stem Cell Institute. 
Available online at http://www.stembook.org, Cambridge, MA, 2009) 
15 Dressler, G. R. Advances in early kidney specification, development and patterning. 
Development 136, 3863-3874, (2009). 
16 Mauch, T. J., Yang, G., Wright, M., Smith, D. & Schoenwolf, G. C. Signals from trunk 
paraxial mesoderm induce pronephros formation in chick intermediate mesoderm. Dev 
Biol 220, 62-75, (2000). 
17 Bellairs, R. & Osmond, M. The atlas of chick development. 2nd edn,  (Elsevier Academic 
Press, San Diego, CA, 2005). 
18 Nieuwkoop, P. D. & Faber, J., eds. Normal table of Xenopus laevis (Daudin).  (Garland 
Publishing, Inc., New York, NY, 1994). 
19 Chan, T. C. & Asashima, M. Development of the embryonic kidney. Clin Exp Nephrol 4, 
1-10, (2000). 
20 Dressler, G. R., Deutsch, U., Chowdhury, K., Nornes, H. O. & Gruss, P. Pax2, a new 
murine paired-box-containing gene and its expression in the developing excretory 
system. Development 109, 787-795, (1990). 
21 Kreidberg, J. A. et al. WT-1 is required for early kidney development. Cell 74, 679-691, 
(1993). 
22 Sainio, K. et al. Glial-cell-line-derived neurotrophic factor is required for bud initiation 
from ureteric epithelium. Development 124, 4077-4087, (1997). 
23 Nigam, S. K. & Shah, M. M. How does the ureteric bud branch? J Am Soc Nephrol 20, 
1465-1469, (2009). 
24 Heffner, L. J. & Schust, D. J. The reproductive system at a glance. 3rd edn,  (Wiley-
Blackwell, Oxford, UK, 2010). 
 105 
25 Reimschuessel, R. A fish model of renal regeneration and development. ILAR J 42, 285-
291, (2001). 
26 Chen, N., Aleksa, K., Woodland, C., Rieder, M. & Koren, G. Ontogeny of drug 
elimination by the human kidney. Pediatr Nephrol 21, 160-168, (2006). 
27 James, R. G. & Schultheiss, T. M. Patterning of the avian intermediate mesoderm by 
lateral plate and axial tissues. Dev Biol 253, 109-124, (2003). 
28 Slack, J. M. W. From egg to embryo: regional specification in early development.  
(Cambridge University Press, Cambridge, UK, 1991). 
29 Bouchard, M., Souabni, A., Mandler, M., Neubuser, A. & Busslinger, M. Nephric lineage 
specification by Pax2 and Pax8. Genes Dev 16, 2958-2970, (2002). 
30 James, R. G. & Schultheiss, T. M. Bmp signaling promotes intermediate mesoderm gene 
expression in a dose-dependent, cell-autonomous and translation-dependent manner. Dev 
Biol 288, 113-125, (2005). 
31 Tsang, T. E. et al. Lim1 activity is required for intermediate mesoderm differentiation in 
the mouse embryo. Dev Biol 223, 77-90, (2000). 
32 Barak, H., Rosenfelder, L., Schultheiss, T. M. & Reshef, R. Cell fate specification along 
the anterior-posterior axis of the intermediate mesoderm. Dev Dyn 232, 901-914, (2005). 
33 Carroll, T., Wallingford, J., Seufert, D. & Vize, P. D. Molecular regulation of pronephric 
development. Curr Top Dev Biol 44, 67-100, (1999). 
34 Dressler, G. R. The cellular basis of kidney development. Annu Rev Cell Dev Biol 22, 
509-529, (2006). 
35 Lang, D., Powell, S. K., Plummer, R. S., Young, K. P. & Ruggeri, B. A. PAX genes: 
roles in development, pathophysiology, and cancer. Biochem Pharmacol 73, 1-14, 
(2007). 
36 Balczarek, K. A., Lai, Z. C. & Kumar, S. Evolution of functional diversification of the 
paired box (Pax) DNA-binding domains. Mol Biol Evol 14, 829-842, (1997). 
37 Plachov, D. et al. Pax8, a murine paired box gene expressed in the developing excretory 
system and thyroid gland. Development 110, 643-651, (1990). 
38 Asano, M. & Gruss, P. Pax-5 is expressed at the midbrain-hindbrain boundary during 
mouse development. Mech Dev 39, 29-39, (1992). 
 106 
39 Torres, M., Gomez-Pardo, E., Dressler, G. R. & Gruss, P. Pax-2 controls multiple steps 
of urogenital development. Development 121, 4057-4065, (1995). 
40 Mansouri, A., Chowdhury, K. & Gruss, P. Follicular cells of the thyroid gland require 
Pax8 gene function. Nat Genet 19, 87-90, (1998). 
41 Carroll, T. J. & Vize, P. D. Synergism between Pax-8 and lim-1 in embryonic kidney 
development. Dev Biol 214, 46-59, (1999). 
42 Bouchard, M., Pfeffer, P. & Busslinger, M. Functional equivalence of the transcription 
factors Pax2 and Pax5 in mouse development. Development 127, 3703-3713, (2000). 
43 Brand, M. et al. Mutations in zebrafish genes affecting the formation of the boundary 
between midbrain and hindbrain. Development 123, 179-190, (1996). 
44 Lun, K. & Brand, M. A series of no isthmus (noi) alleles of the zebrafish pax2.1 gene 
reveals multiple signaling events in development of the midbrain-hindbrain boundary. 
Development 125, 3049-3062, (1998). 
45 Majumdar, A., Lun, K., Brand, M. & Drummond, I. A. Zebrafish no isthmus reveals a 
role for pax2.1 in tubule differentiation and patterning events in the pronephric primordia. 
Development 127, 2089-2098, (2000). 
46 Serluca, F. C. & Fishman, M. C. Pre-pattern in the pronephric kidney field of zebrafish. 
Development 128, 2233-2241, (2001). 
47 Pfeffer, P. L., Gerster, T., Lun, K., Brand, M. & Busslinger, M. Characterization of three 
novel members of the zebrafish Pax2/5/8 family: dependency of Pax5 and Pax8 
expression on the Pax2.1 (noi) function. Development 125, 3063-3074, (1998). 
48 Zheng, Q. & Zhao, Y. The diverse biofunctions of LIM domain proteins: determined by 
subcellular localization and protein-protein interaction. Biol Cell 99, 489-502, (2007). 
49 Hobert, O. & Westphal, H. Functions of LIM-homeobox genes. Trends Genet 16, 75-83, 
(2000). 
50 Barnes, J. D., Crosby, J. L., Jones, C. M., Wright, C. V. & Hogan, B. L. Embryonic 
expression of Lim-1, the mouse homolog of Xenopus Xlim-1, suggests a role in lateral 
mesoderm differentiation and neurogenesis. Dev Biol 161, 168-178, (1994). 
51 Fujii, T. et al. Expression patterns of the murine LIM class homeobox gene lim1 in the 
developing brain and excretory system. Dev Dyn 199, 73-83, (1994). 
 107 
52 Taira, M., Jamrich, M., Good, P. J. & Dawid, I. B. The LIM domain-containing homeo 
box gene Xlim-1 is expressed specifically in the organizer region of Xenopus gastrula 
embryos. Genes Dev 6, 356-366, (1992). 
53 Shawlot, W. & Behringer, R. R. Requirement for Lim1 in head-organizer function. 
Nature 374, 425-430, (1995). 
54 Ariizumi, T. & Asashima, M. In vitro induction systems for analyses of amphibian 
organogenesis and body patterning. Int J Dev Biol 45, 273-279, (2001). 
55 Chan, T. C., Takahashi, S. & Asashima, M. A role for Xlim-1 in pronephros development 
in Xenopus laevis. Dev Biol 228, 256-269, (2000). 
56 Potter, S. S., Hartman, H. A., Kwan, K. M., Behringer, R. R. & Patterson, L. T. Laser 
capture-microarray analysis of Lim1 mutant kidney development. Genesis 45, 432-439, 
(2007). 
57 Mukhopadhyay, M. et al. Dickkopf1 is required for embryonic head induction and limb 
morphogenesis in the mouse. Dev Cell 1, 423-434, (2001). 
58 Lieven, O., Knobloch, J. & Ruther, U. The regulation of Dkk1 expression during 
embryonic development. Dev Biol 340, 256-268, (2010). 
59 Lyons, J. P. et al. Requirement of Wnt/beta-catenin signaling in pronephric kidney 
development. Mech Dev 126, 142-159, (2009). 
60 Campo-Paysaa, F., Marletaz, F., Laudet, V. & Schubert, M. Retinoic acid signaling in 
development: tissue-specific functions and evolutionary origins. Genesis 46, 640-656, 
(2008). 
61 Blomhoff, R. & Blomhoff, H. K. Overview of retinoid metabolism and function. J 
Neurobiol 66, 606-630, (2006). 
62 Menegola, E., Di Renzo, F., Broccia, M. L. & Giavini, E. Inhibition of histone 
deacetylase as a new mechanism of teratogenesis. Birth Defects Res C Embryo Today 78, 
345-353, (2006). 
63 Cartry, J. et al. Retinoic acid signalling is required for specification of pronephric cell 
fate. Dev Biol 299, 35-51, (2006). 
64 Preger-Ben Noon, E., Barak, H., Guttmann-Raviv, N. & Reshef, R. Interplay between 
activin and Hox genes determines the formation of the kidney morphogenetic field. 
Development 136, 1995-2004, (2009). 
 108 
65 Wingert, R. A. et al. The cdx genes and retinoic acid control the positioning and 
segmentation of the zebrafish pronephros. PLoS Genet 3, 1922-1938, (2007). 
66 Bollig, F. et al. A highly conserved retinoic acid responsive element controls wt1a 
expression in the zebrafish pronephros. Development 136, 2883-2892, (2009). 
67 Alarcon, P., Rodriguez-Seguel, E., Fernandez-Gonzalez, A., Rubio, R. & Gomez-
Skarmeta, J. L. A dual requirement for Iroquois genes during Xenopus kidney 
development. Development 135, 3197-3207, (2008). 
68 Desbaillets, I., Ziegler, U., Groscurth, P. & Gassmann, M. Embryoid bodies: an in vitro 
model of mouse embryogenesis. Exp Physiol 85, 645-651, (2000). 
69 Kim, D. & Dressler, G. R. Nephrogenic factors promote differentiation of mouse 
embryonic stem cells into renal epithelia. J Am Soc Nephrol 16, 3527-3534, (2005). 
70 Mainguy, G. et al. A position-dependent organisation of retinoid response elements is 
conserved in the vertebrate Hox clusters. Trends Genet 19, 476-479, (2003). 
71 Taira, M., Otani, H., Jamrich, M. & Dawid, I. B. Expression of the LIM class homeobox 
gene Xlim-1 in pronephros and CNS cell lineages of Xenopus embryos is affected by 
retinoic acid and exogastrulation. Development 120, 1525-1536, (1994). 
72 Tsang, M. Zebrafish: A tool for chemical screens. Birth Defects Res C Embryo Today 90, 
185-192, (2010). 
73 Battle, H. I. & Hisaoka, K. K. Effects of ethyl carbamate (urethan) on the early 
development of the teleost Brachydanio rerio. Cancer Res 12, 334-340, (1952). 
74 Hisaoka, K. K. The effects of 4-acetylaminofluorene on the embryonic development of 
the zebrafish. I. Morphological studies. Cancer Res 18, 527-535, (1958). 
75 Hisaoka, K. K. The effects of 2-acetylaminofluorene on the embryonic development of 
the zebrafish. II. Histochemical studies. Cancer Res 18, 664-667, (1958). 
76 Hisaoka, K. K. & Hopper, A. F. Some effects of barbituric and diethylbarbituric acid on 
the development of the zebra fish, Brachydanio rerio. Anat Rec 129, 297-307, (1957). 
77 Grunwald, D. J. & Eisen, J. S. Headwaters of the zebrafish -- emergence of a new model 
vertebrate. Nat Rev Genet 3, 717-724, (2002). 
 109 
78 Streisinger, G. Attainment of minimal biological variability and measurements of 
genotoxicity: production of homozygous diploid zebra fish. Natl Cancer Inst Monogr 65, 
53-58, (1984). 
79 Hill, A. J., Teraoka, H., Heideman, W. & Peterson, R. E. Zebrafish as a model vertebrate 
for investigating chemical toxicity. Toxicol Sci 86, 6-19, (2005). 
80 Nüsslein-Volhard, C. & Dahm, R. Zebrafish: a practical approach.  (Oxford University 
Press, Oxford, UK, 2002). 
81 Kari, G., Rodeck, U. & Dicker, A. P. Zebrafish: an emerging model system for human 
disease and drug discovery. Clin Pharmacol Ther 82, 70-80, (2007). 
82 Stern, H. M. & Zon, L. I. Cancer genetics and drug discovery in the zebrafish. Nat Rev 
Cancer 3, 533-539, (2003). 
83 Zon, L. I. & Peterson, R. T. In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 
4, 35-44, (2005). 
84 Hirsch, N., Zimmerman, L. B. & Grainger, R. M. Xenopus, the next generation: X. 
tropicalis genetics and genomics. Dev Dyn 225, 422-433, (2002). 
85 Muda, M. & McKenna, S. Model organisms and target discovery. Drug Discov Today 
Tech 1, 55-59, (2004). 
86 Detrich, H. W., Westerfield, M. & Zon, L. I. Essential zebrafish methods: genetics and 
genomics.  (Academic Press, San Diego, CA, 2009). 
87 Bill, B. R., Petzold, A. M., Clark, K. J., Schimmenti, L. A. & Ekker, S. C. A primer for 
morpholino use in zebrafish. Zebrafish 6, 69-77, (2009). 
88 Doyon, Y. et al. Heritable targeted gene disruption in zebrafish using designed zinc-
finger nucleases. Nat Biotechnol 26, 702-708, (2008). 
89 Meng, X., Noyes, M. B., Zhu, L. J., Lawson, N. D. & Wolfe, S. A. Targeted gene 
inactivation in zebrafish using engineered zinc-finger nucleases. Nat Biotechnol 26, 695-
701, (2008). 
90 Bahary, N. et al. The Zon laboratory guide to positional cloning in zebrafish. Methods 
Cell Biol 77, 305-329, (2004). 
91 Guryev, V. et al. Genetic variation in the zebrafish. Genome Res 16, 491-497, (2006). 
 110 
92 Conn, M. P. Sourcebook of models for biomedical research.  (Humana Press Inc., 
Totowa, NJ, 2008). 
93 Postlethwait, J., Amores, A., Cresko, W., Singer, A. & Yan, Y. L. Subfunction 
partitioning, the teleost radiation and the annotation of the human genome. Trends Genet 
20, 481-490, (2004). 
94 Hashiguchi, M., Shinya, M., Tokumoto, M. & Sakai, N. Nodal/Bozozok-independent 
induction of the dorsal organizer by zebrafish cell lines. Dev Biol 321, 387-396, (2008). 
95 He, S. et al. Genetic and transcriptome characterization of model zebrafish cell lines. 
Zebrafish 3, 441-453, (2006). 
96 National Library of Medicine (NLM) and National Institutes of Health (NIH). PubMed 
[electronic resource]. (NLM:NIH, Bethesda, MD). http://www.ncbi.nlm.nih.gov 
/pubmed/. 
97 Brittijn, S. A. et al. Zebrafish development and regeneration: new tools for biomedical 
research. Int J Dev Biol 53, 835-850, (2009). 
98 Sullivan, C. & Kim, C. H. Zebrafish as a model for infectious disease and immune 
function. Fish Shellfish Immunol 25, 341-350, (2008). 
99 Knapik, E. W. ENU mutagenesis in zebrafish--from genes to complex diseases. Mamm 
Genome 11, 511-519, (2000). 
100 Lieschke, G. J. & Currie, P. D. Animal models of human disease: zebrafish swim into 
view. Nat Rev Genet 8, 353-367, (2007). 
101 Moens, C. B., Donn, T. M., Wolf-Saxon, E. R. & Ma, T. P. Reverse genetics in zebrafish 
by TILLING. Brief Funct Genomic Proteomic 7, 454-459, (2008). 
102 Vize, P. D., Seufert, D. W., Carroll, T. J. & Wallingford, J. B. Model systems for the 
study of kidney development: use of the pronephros in the analysis of organ induction 
and patterning. Dev Biol 188, 189-204, (1997). 
103 Pedersen, A., Skjong, C. & Shawlot, W. Lim 1 is required for nephric duct extension and 
ureteric bud morphogenesis. Dev Biol 288, 571-581, (2005). 
104 Drummond, I. Making a zebrafish kidney: a tale of two tubes. Trends Cell Biol 13, 357-
365, (2003). 
 111 
105 Wingert, R. A. & Davidson, A. J. The zebrafish pronephros: a model to study nephron 
segmentation. Kidney Int 73, 1120-1127, (2008). 
106 Picker, A., Scholpp, S., Bohli, H., Takeda, H. & Brand, M. A novel positive 
transcriptional feedback loop in midbrain-hindbrain boundary development is revealed 
through analysis of the zebrafish pax2.1 promoter in transgenic lines. Development 129, 
3227-3239, (2002). 
107 Swanhart, L. M. et al. Characterization of an lhx1a transgenic reporter in zebrafish. Int J 
Dev Biol 54, 731-736, (2010). 
108 Drummond, I. A. et al. Early development of the zebrafish pronephros and analysis of 
mutations affecting pronephric function. Development 125, 4655-4667, (1998). 
109 Kramer-Zucker, A. G., Wiessner, S., Jensen, A. M. & Drummond, I. A. Organization of 
the pronephric filtration apparatus in zebrafish requires Nephrin, Podocin and the FERM 
domain protein Mosaic eyes. Dev Biol 285, 316-329, (2005). 
110 Cianciolo Cosentino, C., Roman, B. L., Drummond, I. A. & Hukriede, N. A. Intravenous 
microinjections of zebrafish larvae to study acute kidney injury. J Vis Exp, (2010). 
111 Hentschel, D. M. et al. Rapid screening of glomerular slit diaphragm integrity in larval 
zebrafish. Am J Physiol Renal Physiol 293, F1746-1750, (2007). 
112 Hentschel, D. M. et al. Acute renal failure in zebrafish: a novel system to study a 
complex disease. Am J Physiol Renal Physiol 288, F923-929, (2005). 
113 Murphey, R. D. & Zon, L. I. Small molecule screening in the zebrafish. Methods 39, 255-
261, (2006). 
114 Wheeler, G. N. & Brandli, A. W. Simple vertebrate models for chemical genetics and 
drug discovery screens: lessons from zebrafish and Xenopus. Dev Dyn 238, 1287-1308, 
(2009). 
115 Peal, D. S., Peterson, R. T. & Milan, D. Small molecule screening in zebrafish. J 
Cardiovasc Transl Res 3, 454-460, (2010). 
116 Sachidanandan, C., Yeh, J. R., Peterson, Q. P. & Peterson, R. T. Identification of a novel 
retinoid by small molecule screening with zebrafish embryos. PLoS One 3, e1947, 
(2008). 
117 Chan, J. & Serluca, F. C. Chemical approaches to angiogenesis. Methods Cell Biol 76, 
475-487, (2004). 
 112 
118 Kokel, D. et al. Rapid behavior-based identification of neuroactive small molecules in the 
zebrafish. Nat Chem Biol 6, 231-237, (2010). 
119 Rihel, J. et al. Zebrafish behavioral profiling links drugs to biological targets and 
rest/wake regulation. Science 327, 348-351, (2010). 
120 Burns, C. G. et al. High-throughput assay for small molecules that modulate zebrafish 
embryonic heart rate. Nat Chem Biol 1, 263-264, (2005). 
121 Vogt, A. et al. Automated image-based phenotypic analysis in zebrafish embryos. Dev 
Dyn 238, 656-663, (2009). 
122 Vogt, A., Codore, H., Day, B. W., Hukriede, N. A. & Tsang, M. Development of 
automated imaging and analysis for zebrafish chemical screens. J Vis Exp, (2010). 
123 Paik, E. J., de Jong, J. L., Pugach, E., Opara, P. & Zon, L. I. A chemical genetic screen in 
zebrafish for pathways interacting with cdx4 in primitive hematopoiesis. Zebrafish 7, 61-
68, (2010). 
124 Anderson, C. et al. Chemical genetics suggests a critical role for lysyl oxidase in 
zebrafish notochord morphogenesis. Mol Biosyst 3, 51-59, (2007). 
125 Peterson, R. T., Link, B. A., Dowling, J. E. & Schreiber, S. L. Small molecule 
developmental screens reveal the logic and timing of vertebrate development. Proc Natl 
Acad Sci U S A 97, 12965-12969, (2000). 
126 Yu, P. B. et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron 
metabolism. Nat Chem Biol 4, 33-41, (2008). 
127 Molina, G. A., Watkins, S. C. & Tsang, M. Generation of FGF reporter transgenic 
zebrafish and their utility in chemical screens. BMC Dev Biol 7, 62, (2007). 
128 North, T. E. et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell 
homeostasis. Nature 447, 1007-1011, (2007). 
129 Cao, Y. et al. Chemical modifier screen identifies HDAC inhibitors as suppressors of 
PKD models. Proc Natl Acad Sci U S A 106, 21819-21824, (2009). 
130 Drummond, I. A. Kidney development and disease in the zebrafish. J Am Soc Nephrol 
16, 299-304, (2005). 
 113 
131 Popa-Burke, I. G. et al. Streamlined system for purifying and quantifying a diverse 
library of compounds and the effect of compound concentration measurements on the 
accurate interpretation of biological assay results. Anal Chem 76, 7278-7287, (2004). 
132 Sussman, C. R. et al. Cloning, localization, and functional expression of the electrogenic 
Na+ bicarbonate cotransporter (NBCe1) from zebrafish. Am J Physiol Cell Physiol 297, 
C865-875, (2009). 
133 Perner, B., Englert, C. & Bollig, F. The Wilms tumor genes wt1a and wt1b control 
different steps during formation of the zebrafish pronephros. Dev Biol 309, 87-96, (2007). 
134 Harris, W. A. & Hartenstein, V. Neuronal determination without cell division in Xenopus 
embryos. Neuron 6, 499-515, (1991). 
135 Westerfield, M. The zebrafish book.  (University of Oregon Press, Eugene, OR, 1993). 
136 Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B. & Schilling, T. F. Stages of 
embryonic development of the zebrafish. Dev Dyn 203, 253-310, (1995). 
137 The NCI/DTP Open Chemical Repository. <http://dtp.cancer.gov>.  
138 Zhang, L., Kendrick, C., Julich, D. & Holley, S. A. Cell cycle progression is required for 
zebrafish somite morphogenesis but not segmentation clock function. Development 135, 
2065-2070, (2008). 
139 Minoru, U., Takao, N. & Kazuyuki, N. Substituted thiobutyric acid derivatives (assigned 
to Otsuka Pharmaceutical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho (1982), 9 pp. 
JP57058663(A) Publication date 1982-04-08 Showa. 
140 Traynelis, V. J. & Love, R. F. Seven-membered heterocycles. I. Synthesis of 
benzo[b]thiepin 1,1-dioxide and 1-phenylsulfonyl-4-phenyl-1,3-butadiene. J Org Chem 
26, 2728-2733, (1961). 
141 Kukalenko, S. S. Organic insectofungicides. I. Synthesis and some reactions of γ-
arylthiobutyric acids. Z Org Khim 6, 680-684, (1970). 
142 Toyama, R., O'Connell, M. L., Wright, C. V., Kuehn, M. R. & Dawid, I. B. Nodal 
induces ectopic goosecoid and lim1 expression and axis duplication in zebrafish. 
Development 121, 383-391, (1995). 
143 Tang, R., Dodd, A., Lai, D., McNabb, W. C. & Love, D. R. Validation of zebrafish 
(Danio rerio) reference genes for quantitative real-time RT-PCR normalization. Acta 
Biochim Biophys Sin (Shanghai) 39, 384-390, (2007). 
 114 
144 Andersen, C. L., Jensen, J. L. & Orntoft, T. F. Normalization of real-time quantitative 
reverse transcription-PCR data: a model-based variance estimation approach to identify 
genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 
64, 5245-5250, (2004). 
145 Ruijter, J. M. et al. Amplification efficiency: linking baseline and bias in the analysis of 
quantitative PCR data. Nucleic Acids Res 37, e45, (2009). 
146 Dong, G. et al. Induction of apoptosis in renal tubular cells by histone deacetylase 
inhibitors, a family of anticancer agents. J Pharmacol Exp Ther 325, 978-984, (2008). 
147 Gurvich, N. et al. Association of valproate-induced teratogenesis with histone 
deacetylase inhibition in vivo. FASEB J 19, 1166-1168, (2005). 
148 Noel, E. S. et al. Organ-specific requirements for Hdac1 in liver and pancreas formation. 
Dev Biol 322, 237-250, (2008). 
149 Lea, M. A. & Tulsyan, N. Discordant effects of butyrate analogues on erythroleukemia 
cell proliferation, differentiation and histone deacetylase. Anticancer Res 15, 879-883, 
(1995). 
150 Hu, P. et al. Retinoid regulation of the zebrafish cyp26a1 promoter. Dev Dyn 237, 3798-
3808, (2008). 
151 Keegan, B. R., Feldman, J. L., Begemann, G., Ingham, P. W. & Yelon, D. Retinoic acid 
signaling restricts the cardiac progenitor pool. Science 307, 247-249, (2005). 
152 Blumberg, B. et al. An essential role for retinoid signaling in anteroposterior neural 
patterning. Development 124, 373-379, (1997). 
153 Bacallao, R. & Fine, L. G. Molecular events in the organization of renal tubular 
epithelium: from nephrogenesis to regeneration. Am J Physiol 257, F913-924, (1989). 
154 Jacobsen, F. E., Lewis, J. A. & Cohen, S. M. The design of inhibitors for medicinally 
relevant metalloproteins. ChemMedChem 2, 152-171, (2007). 
155 Villar-Garea, A. & Esteller, M. Histone deacetylase inhibitors: understanding a new wave 
of anticancer agents. Int J Cancer 112, 171-178, (2004). 
156 Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and 
computational approaches to estimate solubility and permeability in drug discovery and 
development settings. Adv Drug Deliv Rev 46, 3-26, (2001). 
 115 
157 Testa, B., Carrupt, P. A., Gaillard, P., Billois, F. & Weber, P. Lipophilicity in molecular 
modeling. Pharm Res 13, 335-343, (1996). 
158 Peterson, R. T. & Fishman, M. C. Discovery and use of small molecules for probing 
biological processes in zebrafish. Methods Cell Biol 76, 569-591, (2004). 
159 Alexander, J., Rothenberg, M., Henry, G. L. & Stainier, D. Y. casanova plays an early 
and essential role in endoderm formation in zebrafish. Dev Biol 215, 343-357, (1999). 
160 Hughes, I. et al. Otopetrin 1 is required for otolith formation in the zebrafish Danio rerio. 
Dev Biol 276, 391-402, (2004). 
161 Korzh, S. et al. Requirement of vasculogenesis and blood circulation in late stages of 
liver growth in zebrafish. BMC Dev Biol 8, 84, (2008). 
162 Bradner, J. E. et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 6, 
238-243, (2010). 
163 Mundel, P. et al. Rearrangements of the cytoskeleton and cell contacts induce process 
formation during differentiation of conditionally immortalized mouse podocyte cell lines. 
Exp Cell Res 236, 248-258, (1997). 
164 Schwartz, E. J. et al. Human immunodeficiency virus-1 induces loss of contact inhibition 
in podocytes. J Am Soc Nephrol 12, 1677-1684, (2001). 
165 National Center for Biotechnology Information (NCBI) and National Library of Medicine 
(NLM). PubChem [electronic resource]. (NCBI: NLM, Bethesda, MD). 
http://pubchem.ncbi.nlm.nih.gov/. 
166 de Groh, E. D. et al. Inhibition of histone deacetylase expands the renal progenitor cell 
population. J Am Soc Nephrol 21, 794-802, (2010). 
167 Molina, G. et al. Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands 
cardiac cell lineages. Nat Chem Biol 5, 680-687, (2009). 
168 Anderson, R. J., Ray, C. J. & Hattler, B. G. Retinoic acid regulation of renal tubular 
epithelial and vascular smooth muscle cell function. J Am Soc Nephrol 9, 773-781, 
(1998). 
169 Argiles, A., Kraft, N. E., Hutchinson, P., Senes-Ferrari, S. & Atkins, R. C. Retinoic acid 
affects the cell cycle and increases total protein content in epithelial cells. Kidney Int 36, 
954-959, (1989). 
 116 
170 Bonventre, J. V. Dedifferentiation and proliferation of surviving epithelial cells in acute 
renal failure. J Am Soc Nephrol 14 Suppl 1, S55-61, (2003). 
171 Kwon, O. et al. Bone marrow-derived endothelial progenitor cells and endothelial cells 
may contribute to endothelial repair in the kidney immediately after ischemia-
reperfusion. J Histochem Cytochem 58, 687-694, (2010). 
172 Oliver, J. A. et al. Proliferation and migration of label-retaining cells of the kidney 
papilla. J Am Soc Nephrol 20, 2315-2327, (2009). 
173 Imai, N. et al. Inhibition of histone deacetylase activates side population cells in kidney 
and partially reverses chronic renal injury. Stem Cells 25, 2469-2475, (2007). 
174 Marumo, T., Hishikawa, K., Yoshikawa, M. & Fujita, T. Epigenetic regulation of BMP7 
in the regenerative response to ischemia. J Am Soc Nephrol 19, 1311-1320, (2008). 
175 Mitamura, T., Higashiyama, S., Taniguchi, N., Klagsbrun, M. & Mekada, E. Diphtheria 
toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding 
EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic 
activity. J Biol Chem 270, 1015-1019, (1995). 
176 Bock, G. & Goode, J., eds. Reversible protein acetylation.  (John Wiley & Sons Ltd, 
Chichester, UK, 2004). 
177 Furumai, R. et al. Potent histone deacetylase inhibitors built from trichostatin A and 
cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci U S A 98, 87-92, 
(2001). 
178 Sekhavat, A., Sun, J. M. & Davie, J. R. Competitive inhibition of histone deacetylase 
activity by trichostatin A and butyrate. Biochem Cell Biol 85, 751-758, (2007). 
179 Su, H., Altucci, L. & You, Q. Competitive or noncompetitive, that's the question: 
research toward histone deacetylase inhibitors. Mol Cancer Ther 7, 1007-1012, (2008). 
180 Bieliauskas, A. V. & Pflum, M. K. Isoform-selective histone deacetylase inhibitors. 
Chem Soc Rev 37, 1402-1413, (2008). 
181 Balasubramanian, S., Verner, E. & Buggy, J. J. Isoform-specific histone deacetylase 
inhibitors: the next step? Cancer Lett 280, 211-221, (2009). 
182 Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase 
inhibitors. Nat Rev Drug Discov 5, 769-784, (2006). 
 117 
183 Butler, K. V. & Kozikowski, A. P. Chemical origins of isoform selectivity in histone 
deacetylase inhibitors. Curr Pharm Des 14, 505-528, (2008). 
184 Khan, N. et al. Determination of the class and isoform selectivity of small-molecule 
histone deacetylase inhibitors. Biochem J 409, 581-589, (2008). 
185 Richon, V. M. & O'Brien, J. P. Histone deacetylase inhibitors: a new class of potential 
therapeutic agents for cancer treatment. Clin Cancer Res 8, 662-664, (2002). 
186 Schemies, J., Uciechowska, U., Sippl, W. & Jung, M. NAD(+) -dependent histone 
deacetylases (sirtuins) as novel therapeutic targets. Med Res Rev 30, 861-889, (2010). 
187 Hubbert, C. et al. HDAC6 is a microtubule-associated deacetylase. Nature 417, 455-458, 
(2002). 
188 Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M. & Schreiber, S. L. 
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated 
tubulin deacetylation. Proc Natl Acad Sci U S A 100, 4389-4394, (2003). 
189 Sanderson, L. et al. Plasma pharmacokinetics and metabolism of the histone deacetylase 
inhibitor trichostatin a after intraperitoneal administration to mice. Drug Metab Dispos 
32, 1132-1138, (2004). 
190 U.S. Food and Drug Administration (FDA). Drugs@FDA [electronic resource]. (FDA, 
Silver Spring, MD). http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. 
191 Cederbaum, S., Lemons, C. & Batshaw, M. L. Alternative pathway or diversion therapy 
for urea cycle disorders now and in the future. Mol Genet Metab 100, 219-220, (2010). 
192 Ucyclyd Pharma Inc. Buphenyl [electronic resource]. (Ucyclyd Pharma Inc., Scottsdale, 
AZ). http://www.buphenyl.com/. 
193 Lee, B. et al. Phase 2 comparison of a novel ammonia scavenging agent with sodium 
phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and 
ammonia control. Mol Genet Metab 100, 221-228, (2010). 
194 Gilbert, J. et al. A phase I dose escalation and bioavailability study of oral sodium 
phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7, 
2292-2300, (2001). 
195 Buchwald, M., Kramer, O. H. & Heinzel, T. HDACi--targets beyond chromatin. Cancer 
Lett 280, 160-167, (2009). 
 118 
196 Pohl, L. R. & Mico, B. A. Electrophilic halogens as potentially toxic metabolites of 
halogenated compounds. Trends Pharmacol Sci 5, 61=64, (1984). 
197 Hammam, A.-E. G. Some amides, anilides, and bis(hydrazides) of expected biological 
activity. J Chem Eng Data 24, 379-380, (1979). 
 
 
